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Abstract 
To achieve successful gene therapy, safe and efficient gene delivery vectors are 
needed. As an alternative to viral vectors, non-viral vectors, incorporating 
compounds such as cationic polymers and lipids have been widely studied. Much 
effort has been made to enhance transgene delivery efficiency, such as 
development of more effective cationic lipids or polymers, optimization of 
transfection formulations, and investigation on structural-activity of delivery vectors. 
Gemini surfactant, consisting of two surfactant monomers linked by a spacer group, 
is a thrust research area for gene therapy as non-viral vectors due to their high 
stability, longer storage on shelves, easiness to produce.  
A series of phytanyl substituted asymmetric gemini surfactants, phy-3-m (m = 12, 
16, and 18) and phy-7NH-m (m = 12, 16, and 18), were rationally designed and 
synthesized. Due to the bulky nature and increased hydrophobicity of phytanyl 
branch, phy-3-m surfactants showed much lower values of critical micelle 
concentration (CMC) compared to their corresponding symmetric m-3-m. Particle 
size and transmission electron microscopy (TEM) imaging indicate that this type of 
gemini surfactants tends to form stacked bilayers rather than spherical or rod-like 
micelles which are typically observed in gemini surfactants with shorter spacers. 
Phy-3-m surfactants have higher degree of micelle ionization, indicating that the 
counter ions of the gemini surfactants can be easily replaced by other anionic ions, 
such as DNA, which is an advantage of phy-3-m used as transgene vectors.  
  iv 
To evaluate transfection ability, transfection assays were carried out in OVCAR-3 
cells. Transfection complexes formed by a plasmid pVGtelRL, coding enhanced 
green fluorescence protein (EGFP) gene, phy-3-m, and a neutral lipid, 1,2-Dioleyl-
sn-glycerophosphatidylethanolamine (DOPE), at the charge ratios (+/-) of   2:1, 5:1, 
10:1, and 20:1, were incubated with OVCAR-3 cells. Treated cells at all charge 
ratios except 20:1 showed EGFP signals under fluorescence microscopy. 
Meanwhile, EGFP expression and cell toxicity was quantified using fluorescence-
activated cell sorting (FACS). For each gemini surfactant complex, the transfection 
efficiency and cytotoxicity go through a maximum, occurring at different values of the 
charge ratio. Considering both transfection efficiency and cytotoxicity, the optimal 
charge ratio to formulate the complexes containing phy-3-m was found to be 5:1 for 
in vitro transfection. Compared to a positive control, 16-3-16, phy-3-m showed 
higher transfection ability and lower cytotoxicity to OVCAR-3 cells. 
Initial characterization of transfection complexes was investigated by measuring 
particle size and zeta potential. At all charge ratios, transfection complexes were 
positively charged, and greater than +30 mV at 5:1 and 10:1, indicating that the 
complexes would be stable in solution at the ratio above 2:1. Transfection 
complexes were larger at lower charge ratio, but particle size dropped with 
increasing charge ratio (+/-). Comparing particle size and zeta potential with 
transfection efficiency, no correlation between size/zeta potential and transfection 
ability was observed. The larger particles may enter cells through caveolin-mediated 
pathway or phagocytosis, and smaller ones through a clathrin-mediated endocytosis. 
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In addition, phase structures of the complexes were investigated using small angle 
X-ray scattering (SAXS). The complexes containing phy-3-m gemini surfactants 
were found to be able to adopt multiple phase structures, such as L, HII, and other 
highly ordered unidentified phase structures. By contrast, L structure was dominant 
in the transfection complexes formed by 16-3-16. The ability of phy-3-m system to 
adopt multiple phases appears correlated with their higher transfection efficiency in 
OVCAR-3 cells.  
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Chapter 1    Introduction 
1.1 Gene therapy 
Gene therapy is usually defined as the treatment of human disease by transferring 
genetic material into target cells or tissues. With advancements in life science, 
biotechnology, and the significant achievements in the Human Genome Project, a 
number of disease-related genes have been identified. Gene therapies involve the 
replacement of errant genes within the affected cells, or the delivery of genes to 
enhance native proteins in the human body, alter the expression of existing genes, 
or produce cytotoxic proteins or enzymes to kill tumor cells.  
To date, gene therapy has been experiencing a number of major developments. 
Researchers have been trying to improve gene therapy efficiency and reduce 
cytotoxicity in normal tissue through numerous approaches. The first clinical trial of 
gene therapy was performed on two children in the United States in 1990.1 Using a 
retroviral vector, the adenosine deaminase (ADA) gene was transferred into the T 
cells of two children with severe ADA deficiency. Gene treatment was ended after 2 
years. This trial showed the great potential efficacy of using gene-corrected 
autologous cells for treating children with ADA deficiency. The safety problems that 
were observed in later trials had not appeared in such a short term study with few 
patients.  
The use of cationic lipids as a deliver vector in a clinical trial was initiated in 1993.2 
Nabel and colleagues tried to introduce a gene encoding a protein (HLA-B7) into 
  2 
HLA-B7-negative patients with advanced melanoma by injecting DNA-liposome 
complexes. The plasmid DNA was detected in the treated tumor nodules after the 
injection; the recombinant protein (HLA-B7) was observed in the tumor tissue; and 
no antibodies to DNA were detected in the patients. This study demonstrated the 
feasibility, safety, and potential of gene transfer by using liposomes in humans. In 
2003, a research team successfully inserted genes into the brain using modified 
liposomes which shows the potential to treat Parkinson’s disease.3 At the same time, 
the first gene therapy product was approved by the Chinese Drug Regulatory 
Agency, under the trade name Gendicine, consisting of an adenovirus-based 
delivery system that can insert the p53 (tumor suppressor protein) gene into tumor 
cells.4 Clinical trials using Gendicine showed complete tumor regression.5 AdvexinTM 
is another gene therapy product based on the p53 expression.6 In 2006, OncorineTM, 
developed by Shanghai Sunway Biotech, has entered the market.6 In 2012, a gene 
therapy treatment was approved by European Medicines Agency, under the trade 
name Glybera, which is the adeno-associated virus based vector for the treatment of 
the human lipoprotein lipase deficiency.7 To date, a number of genes and delivery 
vectors have been developed and evaluated. Approximately 1340 gene therapy 
clinical trials had been completed by 2007 and over 800 clinical trials in gene 
therapy have been aimed at cancer treatment.5 Unfortunately, the number of 
successful treatments observed in clinical trials has been few.  
For the potential of gene therapy to be realized, there are numerous factors to be 
considered. The therapeutic gene introduced into target cells must be active and the 
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cells must be stable and long-lived. In addition, gene therapy requires the delivery of 
a gene to target cells with high efficiency. Gene delivery vectors must be stable (in 
particular within the blood stream), must be able to cross membrane barriers 
including blood vessels and other tissues, and should specifically bind to the target 
cells. Therefore, the optimization of the delivery system has become a key step in 
the development of a safe and efficient human gene therapy. An ideal gene delivery 
system, described by Figure 1.1, should 1) transport the DNA across the plasma 
membrane and into the nucleus of target cells; 2) protect the therapeutic gene from 
degrading by serum and nucleases; 3) release the therapeutic gene easily in the  
 
 
 
 
 
 
 
 
Figure 1.1 Summary of various steps involved in an ideal delivery vector. These 
steps are: 1) transport the DNA across the plasma membrane and into the nucleus 
of target cells; 2) protect the therapeutic gene from degrading by serum and 
nucleases; 3) release the therapeutic gene easily in the nucleus; 4) target specific 
cells of interest; 5) be easily formulated and cost-effective to synthesize; 6) efficiently 
compact any size of DNA and unpack the DNA inside the cells; and 7) have low 
immunogenicity and cytotoxicity.  
7 
Delivery vector 
carrying DNA 
Targeted Cell    4 
1 
1 2,3 
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Invagination of the  
Cell membrane 
lysosome
s 
Endosome escape 
Early endosome 
6 
2 
DNA 
delivery  
vector 
5,6 
x 
  4 
nucleus; 4) target specific cells of interest; 5) be easily formulated and cost-effective 
to synthesize; 6) efficiently compact any size of DNA and unpack the DNA inside the 
cells; and 7) have low immunogenicity and cytotoxicity.  
 
1.2 Gene delivery vectors 
Gene delivery vectors can be divided into three major categories: naked DNA or 
plasmid delivered by physical transfer techniques, such as the gene gun, needle 
injection, and electroporation; viral vectors, such as adenovirus, retrovirus, assisted-
adenovirus, among others; and nonviral vectors, including those formed from 
cationic polymers and cationic lipids. Each gene delivery system will be described in 
more detail below. 
1.2.1 Naked DNA  
Naked DNA or plasmid DNA can be directly injected into a target tissue or cell 
without the need of any additional delivery vector. Direct injection has been used in 
muscle,8 liver,9, 10 skin,11 or lung tissues.12 The method is simple (although time-
consuming) and less toxic to cells; however, gene delivery with naked DNA leads to 
a very low gene expression because the negatively charged DNA is generally 
repelled from the negatively charged cell membrane. There is also difficulty in 
passing through nuclear pores if entry into the cells is achieved. In addition, the 
large DNA molecules are easily bound by blood serum albumin and other negatively 
charged proteins, leading to the removal by phagocytic cells and the 
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reticuloendothelial system,13 or the naked DNA is degraded by nucleases which 
reduce the chance of DNA entering the nucleus.14  
Naked DNA has also been introduced into cells by employing mechanical and 
electrical strategies, such as the gene gun and electroporation. In the gene gun 
method, DNA is deposited on the surface of gold particles, then accelerated by 
compressed gas into cells or tissues.14 Disadvantages of this method include: the 
gold particles can only penetrate a few millimeters deep into tissue; the nano-sized 
particles are limited in terms of the size of DNA that can be carried; and there are 
inconsistencies in the coating of the gold particles by DNA. Advantages of the gene 
gun method are that it is simple to operate and effective in delivering genes. 
Electroporation, commonly used ex vivo, has been extensively used in many types 
of tissues, such as skin15 and muscles.16 Compared to direct injection of naked DNA, 
the reported gene expression obtained from such a strategy has been observed to 
be 2 to 3 orders of magnitude higher.17 It has also been reported that large plasmids 
(i.e. 100 kilobase pairs) can be effectively delivered into muscle cells.18 However, 
several drawbacks exist with respect to the in vivo application of electroporation. It is 
only effective on a limited range of tissue between two electrodes, and is also 
invasive. Before electroporation, a procedure is required to insert two electrodes into 
the target internal organs. The high voltage applied to the tissue can result in the 
damage of the tissue because of the thermal heating.19 Although transfection 
efficiencies are significant using the gene gun or electroporation, they are  difficult to 
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standardize in human clinical trials and are considered laborious and impractical.20 
Therefore, these types of techniques will likely be unsuccessful in the long term. 
1.2.2 Viral vectors 
In viral delivery vectors, the therapeutic gene is assembled in the viral genome and 
the virus then uses its own infection mechanisms to enter target cells and release 
the transgene in the cytoplasm. The gene is then transported to the nucleus of the 
host cells through cytoskeletal transport, transcription factors, and importins, and is 
eventually expressed.21 Viruses such as adenovirus, retrovirus, and adeno-
associated virus, are most commonly being used to transfer DNA, although there are 
others. Viral vectors are capable of delivering transgenes to numerous cell lines with 
high transfection efficiency; currently, viral vectors are used in more than 70% of 
human clinical gene therapy trials,5 such as commercially available gene therapy 
products, GendicineTM, AdvexinTM, and OncorineTM, and a recently approved 
product, GlyberaTM.   
Compared to other delivery vectors, the most significant advantage of viral vectors 
is their very high transfection efficiency. To date, more than 50 human and many 
nonhuman subgenuses of the adenovirus have been used to mediate gene delivery 
to a wide range of tissues, such as eye, liver, urinary tract,22-24 etc. Adeno-
associated viruses have become ideal candidates for gene delivery because these 
vectors can mediate long-term gene expression in many dividing and non-dividing 
cells in vivo.25 26 Retroviruses are a family of enveloped viruses with a singled 
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stranded RNA genome.27 To date, around 45%-95% of primary human endothelial 
and smooth muscle cell types, some of which are extremely difficult to transfect, 
have been transfected by retroviral vectors.28  
Despite such a large advantage in terms of increased transfection efficiencies, 
several significant limitations in use of viral vectors exist. The primary concern is that 
of safety, and the potential of a strong immune response caused by the viral capsid 
proteins.29-31 Jessi Gelsinger was unfortunately the first person to die in a clinical trial 
for gene therapy in 1999. He joined a clinical trial run by the University of 
Pennsylvania and was treated with an adenoviral vector carrying a gene to correct 
ornithine transcarbamylase (OTC) deficiency in order to test the safety of the vector 
and the gene therapy protocol. He died four days later as a result of a massive 
immune response triggered by the use of the viral vector, resulting in multiple organ 
failure and brain death.32 The decision to include Jessi in the trial was strongly 
criticized since the disease had been well controlled.  
In addition to an immune response, insertion mutation can occur, and possibly 
results in genetic disorders if the transgene is not inserted in the DNA sequence 
accurately. Retroviral gene therapy used to treat X-linked severe combined 
immunodeficiency (X-SCID) has been the most successful application of gene 
therapy so far.33 An unfortunate outcome of this trial was that several children have 
developed leukemia as a result of insertion mutation by the retroviral vector.34 Other 
factors also limit the use of viral vectors for gene therapy, such as a limit in the size 
of the therapeutic gene to carry because the viral envelope has a finite capacity,35 
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and the significant costs associated with the scale-up and production of viral 
vectors.36 Given these concerns, alternatives to viral vectors are in high demand, 
driving research into the development of highly efficient non-viral vectors. 
1.2.3 Non-viral vectors 
As stated above, non-viral vectors are generally comprised of cationic polymers or 
cationic lipids, and may include additional polymers or lipids to improve their overall 
efficiency. These vectors rely on the electrostatic interaction between the cationic 
lipid or polymer and the anionic DNA to efficiently compact and deliver the DNA into 
cells. Non-viral vectors, generally, have much lower immunogenicity and cytotoxicity 
than viral vectors; there is no limitation on the size of DNA that can be delivered; and 
they can be manufactured and stored easily using standard good manufacturing 
practice (GMP) methods.37, 38 
1.2.3.1 Cationic polymers 
Currently, the most widely studied polymers for gene delivery include 
polyethylenimine (PEI), poly (L-lysine) (PLL), chitosan, and polyamidoamine 
(PAMAM) dendrimers (Table 1.1). The complex formed by cationic polymers and 
DNA is called a polyplex. Cationic polymers bind DNA with certain functional groups, 
such as primary, secondary, and tertiary amines. Due to the abundance of amine 
groups within the structure of the polymers, a very popular mechanism for 
polyplexes escaping endosomes, called the proton-sponge hypothesis, has been 
proposed.39-41 The proton-sponge mechanism is described as following.  
  9 
Table 1.1 The structure of common studied cationic polymers used for gene delivery. 
Generic name Chemical name Chemical strucuture 
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At physiological pH, amines of proton-sponge polymers, such as PEI and chitosan, 
are not fully charged, but they are protonated in endosomes because of acidic 
conditions that exist in endosomes. Endosomes are acidified through an ATPase 
enzyme that actively transports protons from the cytosol into the endosomes. Due to  
the protonation of the polymers, larger quantities of protons are pumped into 
endosomes to reach the endosomal pH. The accumulation of protons in the 
endosomes must be balanced by chloride ions and the increased chloride ion 
concentration raises the osmotic pressure, causing osmotic swelling and rupture of 
the endosome membranes, thus releasing the polyplexes into the cytosol. The 
hypothesis has been quantitatively verified through comparing the transfection 
activity before and after the removal of protonable amines.39, 40, 42 
PEI is one of the most popular cationic polymers capable of gene transfection. 
Transfection efficiency is reported to increase with increased molecular weight.43 
The most active PEI reported has a molecular weight of 25 kDa, but also shows high 
cell toxicity. Compared to PEI, PLL exhibits lower transfection efficiency mostly 
because of the lack of rapid release of the complexes from the endosomes. All 
primary amino groups of PLL are already protonated at physiological pH, thus no 
proton sponge mechanism occurrs in endosomes.44  
Chitosan, a naturally occurring polymer, is a linear polysaccharide and produced 
by the deacetylation of chitin.45 Due to its biodegradability, biocompatibility, and low 
toxicity, chitosan has become an attractive component for non-viral vectors. It has 
been shown that the molecular weight of chitosan can strongly affect gene 
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transfection efficiency.46 Chitosan with high molecular weight can form more stable 
complexes with DNA due to a chain entanglement effect which is defined as an 
effect that polymer molecules with long chains can become entangled with one 
another.47 In addition, transfection efficiency increases with the molecular weight of 
chitosan because the high molecular weight polymers can entrap DNA more 
efficiently than low molecular weight polymer does. Chitosan with lower molecular 
weight was reported to be less efficient at retaining the DNA upon dilution, which 
results in it being less capable of protecting the condensed DNA from the 
degradation by DNase and other serum component.48 
Another novel class of macromolecular polymers called “dense star” polymers are 
the polyamidoamine dendrimers. Dendrimers are highly symmetric, spherically 
shaped compounds, and are dominated by specific functional groups on the surface, 
such as amino acid residues which can complex with DNA. Bielinska et al. showed 
that transfection efficiency was influenced by both the dendrimer-DNA charge ratio 
and the dendrimer generation.49 At a charge ratio less than 1, the DNA-polymer 
complexes are soluble but do not compact; at charge ratios between 1 and 100, 
insoluble complexes are formed; and at higher charge ratios (greater than 100), 
resolubilization occurs.50 The higher generation structures were more efficient in 
condensing DNA because the dendrimers of higher generation contain larger 
fractions of tightly bound DNA regions.51 
1.2.3.1.1  Strategies for improving cationic polymer mediated gene delivery  
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To improve cationic polymer mediated gene transfection, various strategies have 
been investigated, such as PEGylation, copolymer synthesis, and other chemical 
modifications. PEGylation is the most common modification, which conjugates 
polyethylene glycol (PEG) to cationic polymers. This modification can increase both 
the stability of polyplexes and circulation time by reducing the interaction of the 
polyplexes with serum proteins and other blood components.45 It has been shown 
that a high density of relatively short PEG grafted onto PEI achieved an extremely 
significant DNA transfection.52, 53 Similarly, Kim et al. showed that the attachment of 
PEG to PAMAM significantly improved gene transfection efficiency and lowered the 
cytotoxicity.54 Although PEGylation is helpful in increasing the stability of polyplexes, 
the conjugation of PEG to polymers may decrease the surface charges that can lead 
to reduced interaction with the cell membrane, lowering the cellular uptake of the 
polyplexes.55  
In addition to using PEGylated polymers, improvements have been observed 
using other copolymer synthesis. The conjugation of chitosan and polylysine showed 
increased transfection efficiency and reduced toxicity compared to chitosan and 
polylysine individually.56 It was shown that the copolymer can bind and condense 
plasmid DNA much better than the individual polymers, which contributed to the 
enhanced transfection efficiency. Another study reported a copolymer of PAMAM-
PLL which showed a better ability to bind and condense DNA with the PLL moiety, 
and an increased buffering capacity to facilitate endosomal release offered by the 
PAMAM segment.57 
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Another strategy used to improve cationic polymer mediated transfection is to 
modify the chemical structure of the cationic polymer. To increase charge density, 
the quaternized modification of chitosan, such as trimethylated chitosan, was 
examined, resulting in improved transfection efficiency but with increased 
cytotoxicity.58, 59 To improve transfection efficiency, the amine functionality of PEI 
has been modified. By linking cholesterol to the secondary amine groups of PEI, 
Wang et al.60 found that the modified PEI with low molecular weight showed 
increased transfection efficiency and reduced toxicity. The authors believe that the 
conjugation through the secondary amines gives the modified PEI special advantage 
because the free primary amino groups have a significant role in DNA condensation. 
Also, the conjugation leaves enough space for the steric interactions of the PEI’s 
primary amines with the DNA. It has been reported that a modified PAMAM having a 
more flexible structure was developed which also showed improved transfection 
efficiency. This result was attributed to a more efficient endosomal release resulting 
from the flexible structure.45 Some of the modified PAMAM polymers have become 
commercial products, such as Superfect and Polyfect (Qiagen), used as standards 
in gene transfection assay for comparison.61  
1.2.3.2 Cationic lipids 
A cationic lipid consists of a cationic head group, usually two hydrophobic moieties, 
and the linker between two portions. Since the first cationic lipid, N-[1-(2,3-
dioleyoxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), was reported to 
transfect cells in vitro in 1987,62 a number of cationic lipids have been designed and 
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developed for gene therapeutics. The commonly used cationic lipids include 1,2-
dioleyl-3-trimethylammonium propane (DOTAP), DOTMA, 2,3-dioleyloxy-N-[2-
(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium (DOSPA), dioctadecyl  
amido-glycylspermine (DOGS), and 3β-[N-(N′, N′-dimethylaminoethane)-carbamoyl] 
cholesterol ( DC-chol). Their chemical structures are shown in Table 1.2. These 
lipids differ in the number of charges in their hydrophilic head group and/or in the 
structure or length of their hydrophobic tail groups. The chemical structure of cationic 
lipids plays an important role in transfection efficiency. The effect of variations in 
these groups with respect to transfection efficiency is discussed in more detail 
below.  
1.2.3.2.1 Effect of head-group structure 
The density and nature of the head group has been shown to influence gene 
transfection efficiency.45, 63 In general, lipids with multivalent head groups and long, 
unsaturated hydrocarbon tails show more efficient transfection than those with 
monovalent head group and the same length and type of hydrocarbon tails. The 
multivalent lipids increase DNA binding and thus significantly enhance lipid-mediated 
gene delivery.45, 64 The commercial product, LipofectamineTM 2000 (Invitrogen), 
consisting of DOSPA with five quaternary ammonium groups in the head portion, is 
an example of a vector incorporating such lipids.65  
While DNA binding increases with an increased number of cationic groups within 
the head group, it has also been shown that the spacing between the ammonium 
groups of a multivalent head group strongly influences transfection efficiency.  
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Table 1.2 Common cationic lipids used for gene delivery.45 
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Chemical structure 
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For cationic lipids with a tetraammonium head group, a decrease in the spacing 
between ammonium groups from four to two methylene groups resulted in reduced 
transfection activity. The results showed that at a neutral pH, the positive charges of 
the cationic lipids with a spacing of four and two methylene groups were 2.4 and 1.8, 
respectively. The authors believe that the significantly different positive charge 
distribution caused by the different methylene spacing may result in the significant 
difference of the transfection efficiency observed in the study.66 
In addition to the effect on positive charge distribution, the spacing between head 
groups influences the lipid structures, resulting in different transfection activity. To 
design cone-shaped vectors as a means of inducing the formation of inverted 
hexagonal structures, Gaucheron et al. synthesized tetraalkylated cationic lipids.67 
Two derivatives of the cationic lipid N,N-dioleyl-N,N-dimethylammonium chloride 
(DODAC), have been synthesized: N,N,N’,N’-tetraoelyl-N,N’-dimethyl-1,3-
propanediammonium chloride (TODMAC3) and N,N,N’,N’-tetraoelyl-N,N’-dimethyl-
1,6-hexanediammonium chloride (TODMAC6), which has three and six methylene 
groups between the ammonium head groups, respectively. It was found that when 
mixing with anionic lipids, TODMAC6 was more prone to forming nonbilayer 
structures than TODMAC3. Also, TODMAC6 showed greater transfection capacity 
than TODMAC3.67 This observation is also found in the gemini surfactants with one 
N-CH3 substitution in the spacer: 12-5N-12 and 12-7N-12. SAXS profiles obtained 
from the complexes containing 12-5N-12 showed a lamellar structure, while an 
additional unidentified phase was observed in the complexes containing 12-7N-12. 
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This may explain why 12-7N-12 demonstrated a higher luciferase expression in 
COS7 cells than 12-5N-12 did. It is believed that lipoplexes with nonlamellar phase 
structures are more amenable to membrane fusion with endosomal lipid 
components. This facilitates the DNA release from lipoplexes and thus leading to a 
higher transfection efficiency.  
 In addition, the modification of the head group of monovalent phospholipids by 
replacing the ammonium group with different monovalent cationic moieties has been 
investigated. Gene transfection has shown that phospholipids with arsonium (As) 
and phosphonium (P) ions achieve significantly lower cytotoxicities than the 
ammonium (N) analogues.68 The reduced toxicity was attributed to the increased 
atomic radii of As and P compared to N. The replacement of the ammonium group 
with As or P may result in the formation of the larger cationic complexes with 
reduced charge densities.45 Another report has shown that surfactants with a 
cationic pyridinium head group showed 3 to 6-folder higher tranfection efficiency in 
vivo than that of Lipofectin, a commercially available cationic lipid which is the 
mixture of DOTMA and DOPE.69 It has been proposed that the higher transfection 
efficiency would be related to the formation of vesicular aggregates of this type of 
cationic lipid.45  
1.2.3.2.2 Effect of tail-group structure 
The manipulation of the hydrophobic portion, such as the length or the saturation of 
tails, also affects the transfection efficiency. The effect of length of the hydrocarbon 
tails on gene transfection is conflicting. Several studies have shown that gene 
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transfer increases with reduced chain length;70, 71 while a decrease in the carbon 
length from 18 to 12 resulting in the reduced transfection efficiency was observed in 
a polyamine lipid 72 and polylysine based surfactants;73 it has also been reported that 
there is no correlation observed between lipid chain length and transfection 
efficiency for lipospermine derivatives.63 
Regardless, modification(s) or various alternatives of the alkyl chain(s) have been 
examined to improve gene transfection. For example, cholesterol and other steroidal 
groups have been investigated as replacements for the aliphatic tails of lipids 
because of favorable properties such as their rigidity, biodegradability, and fusogenic 
capacity37, 74. Cholesterol was first incorporated to form 3-[N-(N’,N-
dimethylethylenediamine)-carbamoyl] cholesterol (DC-Chol) lipid by Huang et al.,75 
and subsequently other cholesterol based cationic lipids have been designed and 
investigated, such as bis(guanidinium)-tren-cholesterol (BGTC) and 3-[6’-
kanamycin-carbamoyl] cholesterol (KanaChol).76, 77 BGTC has been reported to 
deliver DNA into cells through a different pathway of endosomal escape from other 
cationic lipids, such as dioleyl succinyl paramomycin (DOSP).78 DNA was 
dissociated partially or completely from the BGTC before endosomal escape, while 
for DOSP, DNA release from the lipoplexes may concomitantly escape from the 
endosomes. These different pathways of endosomal escape could contribute to their 
difference in transfection efficiency.  
 The incorporation of unsaturated bond(s) to the hydrophobic portion of the lipids 
can improve gene transfer by promoting endosomal escape and disassociation of 
  19 
DNA from the lipoplexes. A series of cationic lipids with 0, 1, 2, or 3 double bonds 
were synthesized (their structures are listed in Figure 1.2) and the correlation 
between lipid saturation, phase transition temperature, and transfection efficiency in 
vitro was investigated.79 The results have shown that the temperature of phase 
transitions from the lamellar to inverted hexagonal structures increases with an 
increase in saturation; and the highest gene expression efficiency was achieved with 
particles containing lipids with two double bonds; particles containing lipids with 3 
unsaturated bonds showed the second highest efficiency; 31P-NMR analysis 
determined that lipids with two double bonds had the lowest phase transition 
temperature, being the most fusogenic lipid.79   
 
   
Figure 1.2 Chemical structures of the cationic lipids with 0, 1, 2, or 3 double bonds.79 
Lipids in which the two alkyl chains are of different length have also been 
examined. It has been reported that the combination of C12/stearyl or C12/oleoyl may 
result in vectors with increased fusogenicity, which facilitates endosomal escape.71, 
80  Asymmetric lipids showed in vitro activities superior to the best symmetric 
analogues; 80 however, the degree of asymmetry influences gene transfection 
activity. A small degree of asymmetry (e.g. C12:C8 and C14:C8) showed the best in 
vitro activity, while highly asymmetric compounds (C18:C8) performed poorly. 
80 The 
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lipid with a high degree of asymmetry (C18:C8) was hypothesized to form micelles 
instead of bilayer structures. This could lead to its inefficient transfection.37 A 
conflicting result was obtained for a series of dialkyl lipids containing either C12, C14, 
C16, C18 or Coleyl chains; the best tansfection activity was observed for the 
asymmetric lipids with one tail C12 and the other C18 or Coleyl.
71 The above results 
indicate that high transfection efficiency may require both the appropriate degree of 
asymmetry (increased fusogenicity of lipids) and also the formation of the lipid 
bilayer structures.  
1.2.3.2.3 Lipoplex composition and structure 
Typically, lipoplexes are prepared by mixing cationic liposomes and DNA in a buffer 
solution. The formation of the lipoplex is mainly driven by electrostatic interaction 
between the positive charged cationic lipid head groups and the negative charged 
phosphate backbones of DNA.81 This step is simple but very important in 
determining the characteristics and transfection efficiency of lipoplexes. Thus, any 
protocol for lipoplex formation should consider the charge ratio of lipoplex to DNA, 
incubation conditions (temperature and time), and mixing order.  
It is believed that use of an excess of cationic lipids result in a higher transfection 
efficiency.62, 82 This result has been attributed to more efficient interaction between 
lipoplexes with a net positive charge and the negatively charged cell membrane.83 
Lipoplex size has also been shown to be a function of lipid-DNA charge ratios.83-85 At 
high charge ratios, lipoplex particles are generally homogeneous and small, while at 
charge ratios close to neutrality, lipoplexes tend to form larger and less stable 
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aggregates. Precipitation of lipoplexes has been reported at neutral or a slight 
excess of positive charge.83-85  
Charge ratio also impacts the extent to which DNA can be condensed and 
protected against degradation by cellular nucleases. It was reported that the 
accessibility of ethidium bromide to DNA dropped with increasing of the charge 
ratios, implying better compaction and protection at higher charge ratios.86 
Unfortunately, given that the cationic charge carriers in lipids are generally 
quaternary ammonium groups, lipoplexes prepared at high charge ratios generally 
also exhibit higher cytotoxicity because of the high number of free quaternary 
ammonium groups.81   
The structure of lipoplexes has been shown to correlate to gene transfection 
efficiency. Lipoplex structures have been examined by biophysical and thermal 
techniques, such as electron microscopy (EM), small angle X-ray scattering (SAXS), 
differential scanning calorimetry (DSC),87-89 and isothermal titration calorimetry 
(ITC)88, 90 among others. Freeze-fracture EM images have revealed lipoplexes with 
both spherical structures (representing liposomes) and filamentous structures 
(representing the DNA surrounded by a lipid bilayer).84, 91, 92 SAXS has been applied 
to investigate lipoplex structures, such as the inverted hexagonal (HII) structure, 
lamellar (L) structure, and other highly ordered structures.
93, 94 Lamellar structures 
consist of DNA molecules that are sandwiched between lipid bilayers in an 
alternating fashion. The inverted hexagonal morphology is one where DNA “rods” 
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are coated with the lipid monolayers which are then arranged on a hexagonal 
lattice.95 Their structures are illustrated in Figure 1.3. 
 
 
 
 
 
Figure 1.3 Schematic pictures of the Lamellar (left) and inverted hexagonal (right) 
phase structures of lipoplexes.96 The bilayer spacing is m, the spacing for 
intercalated monolayer of DNA is w, and interlayer spacing for lamellar complexes is 
d = m +  w. For an inverted hexagonal phase of lipoplexes, a unit cell spacing (a) is 
the distance between the centers of two neighbouring rods.    
Lipoplex structure depends on the structure of a cationic lipid, the charge ratio of 
lipids to DNA (introduced above), the structure of any helper lipids (the common 
used helper lipids are listed in Table 1.3), and their mole ratio with respect to the 
cationic lipid(s). At physiological conditions, most phospholipids adopt a lamellar 
structure.97 Generally, lipids with the L crystal structure prefer to form L structures 
within lipoplexes, with the DNA molecules organized between lipid bilayers.98, 99 
Phospholipids such as DOPE (1,2-dioleoyl-sn-glycerophosphatidylethanolamine), 
with relatively small head groups and longer or unsaturated alkyl chains have a 
tendency to form the HII phase. DOPE is a helper lipid which is generally used to 
incorporate with a cationic lipid for gene transfection. DOPE was reported to 
undergo a phase transition from L to HII structures at neutral pH and temperature 
w 
m 
Lipid 
DNA rod 
DNA Rod 
Neutral Lipid 
Cationic Lipid 
a 
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above 10-15 ºC.100 Although cationic lipids such as DOTAP and DOTAM, prefer to 
form L structures, the incorporation of DOPE with this type of lipids influences the 
packing geometry and results in a rearrangement of the liposomes. Thus, when 
mixed with DOPE, phase transitions were observed for DOTMA101 or DOTAP 
liposomes.102  
Table 1.3 Common helper lipids used for gene delivery. 
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Additionally, the amount of a neutral lipid can affect lipoplex morphology. Different 
weight ratios of a cationic lipid to a neutral lipid in liposomes can produce different 
lipoplex structures. The phase transition from L to HII can be manipulated in terms 
of the adjustment of the neutral lipid amount in the total lipids. Koltover et al. 
investigated lipoplex structures at various concentration of DOPE with a fixed ratio of 
DOTAP to DNA.96 At a weight fraction DOPE/(DOPE+DOTAP) of 0.41, SAXS 
profiles showed a lamellar morphology; at 0.65, a mixed structure of L and HII 
phases was observed; at 0.75, SAXS results showed the HII phase structure only; 
and at 0.87, the coexistence of the HII lipoplexes and inverted HII pure DOPE was 
obtained. The phase transition caused by changing the weight ratio of DOPE is 
believed to be attributed to the interplay between the electrostatic and membrane 
elastic interactions.103 The membrane elastic energy favors a curved interface.103, 104 
DOTAP, with the head group area roughly equal to the hydrophobic tail area, tends 
to form lamellar Lstructures. While DOPE with larger volume of two chains and 
smaller head group area, forms an inverted HII phase. The actual curvature of the 
lipid mixture depends on the fraction of DOPE in the mixture and the natural 
curvature of DOPE itself. With an increase in the fraction of DOPE in the mixture, the 
actual curvature is more negative, indicating the membrane elastic energy is 
dominant. This results in a transition of the lipid mixture from the lamellar to the 
hexagonal phase. Thus, the manipulation of weight fraction of neutral lipid in the lipid 
mixture can change the final structure of the lipoplexes formed. 
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1.3 Barriers involved in lipid-based gene delivery system 
Gene delivery vectors face numerous barriers in transporting transgenes from a test 
tube to a target cell nucleus. The physicochemical properties of the cationic and 
neutral lipids that comprise the lipoplexes, and properties of lipoplexes themselves 
influence the ability of lipoplexes to overcome these barriers. Some of the important 
barriers include stability in the blood serum, targeting to specific cells, the cellular 
internalization pathway, endosomal escape, and nuclear entry; these will be 
discussed in detail in the following sections.  
1.3.1 Cellular binding 
As early steps in the gene transfection process, the mechanism(s) by which 
lipoplexes bind to the cell surface and their subsequent internalization have been 
examined widely. The binding process is believed to be driven by electrostatic 
interactions between positively charged lipoplexes and the negatively charged cell 
surface.83, 105 There is limited data on the importance of specific cell surface 
receptors and possible roles of cell surface components with respect to the binding 
of lipoplexes to the cellular membrane, although heparan sulfate proteoglycans 
(HSPGs) have been implicated in the binding of lipoplexes.106, 107 HSPGs are a class 
of membrane-anchored proteins and function as specific growth factor receptors. 
They have been shown to mediate the cellular entry of pathogens.108, 109  
HSPG mediated binding in transfection was demonstrated by using proteoglycan-
deficient Chinese hamster ovary (CHO) mutant cells.110 These mutant cells showed 
much lower transfection efficiency when using poly-L-lysine and cationic lipids 
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vectors as compared to the normal cells. Furthermore, the results showed the 
inhibition of intracellular DNA uptake and DNA binding to the cell membrane. These 
results were confirmed using Hela cells treated with specific enzymes that degrade 
proteoglycans.110 However, the distribution of HSPGs varies in cells, which may 
explain why some cell types are more accessible to transfection complexes. 
An ideal gene delivery vector can target and kill cancer cells while affecting as few 
healthy cells as possible. To improve cellular binding and the effectiveness of gene 
delivery, a variety of targeting ligands has been studied. Transferrin, epidermal 
growth factor (EGF), and folic acid, have been widely examined as cancer-targeting 
delivery systems. The cationic polymer, PEI, conjugated to transferrin or EGF 
through a linker of polyethylene glycol (PEG) showed luciferase production 10-100 
times higher in tumor models than in other organs.111 The folate receptor is 
abundantly expressed on the surface of cancer cells, which makes folic acid an 
excellent target ligand for a number of types of cancer, such as the ovary, lung, 
breast kidney, brain, colon, etc.112, 113 Liposomes conjugated to folate target ligand 
through a PEG spacer have been used to deliver therapeutic agents to cancer 
cells.114-116 Some researchers have also studied folate-linked microemulsions as 
carriers for chemotherapeutic agents in cancer cells .117, 118 In vitro and in vivo 
studies showed that folate modification with a PEG linker on emulsions is an 
effective way to target emulsions to cancer cells.118  
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1.3.2 Cellular uptake 
Once bound to the cell surface, internalization of the lipoplexes must take place. It 
has been revealed using electron and fluorescence microscopy that lipoplexes can 
be found in intracellular vesicles, indicating that lipoplexes enter cells by 
endocytosis.92 To date, the widely accepted internalization pathway for lipoplexes is 
through endocytosis, including phagocytosis, macropinocytosis, clathrin-mediated 
and non-clathrin-mediated (cellular entry via caveolae) endocytosis;119 however, 
which endocytotic pathway is involved may be specific to a particular cell type. Using 
lipoplexes composed of the cationic lipid SAINT-2 (Figure 1.4) and DOPE, Zuhorn et 
al. have shown a cholesterol-dependant endocytosis pathway in African green 
monkey kidney cell line (COS-7), Human hepatocellular liver carcinoma cell line 
(HepG2), and CHO cells.120 Simoes and colleagues concluded that a non-clathrin-
coated-pit pathway (clathrin-independent endosytosis) was involved in the 
internalization of the DOTAP-DOPE/DNA lipoplexes in Hela cells.121 The 
examination of gene transfection using different lipoplexes and cell lines concluded 
that for primary cells, binding and endocytosis are important rate-limiting steps for 
the transfection efficiency,122-124 while for established cell lines, such as COS cells, 
Hela cells, endocytosis is not a rate-limiting step.125, 126   
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Figure 1.4 The molecular structure of SAINT-2 
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 Lipoplex size seems related to cellular entry pathway. Lipoplexes with a size of 
150-800 nm were reported to be internalized by clathrin-mediated endocytosis;120, 127 
however, Grosse et al. have reported that particles larger than 200 nm may be 
internalized via macropinocytosis, rather than via a clathrin-mediated pathway.128 
Although particle size is an important parameter in gene transfection, a direct 
correlation between particle size and the entry pathway of lipoplexes has not been 
universally demonstrated or accepted.  
1.3.3 Endosome escape 
Following endocytosis, lipoplexes are internalized to form early endosomes. 
Generally, endosomes undergo a rapid maturation and late endosomes end up by 
fusing with lysosomes. This is not expected to be efficient for transfection since the 
lipoplexes tend to be degraded in lysosomes. Thus, it is essential that lipoplexes 
carrying DNA escape the early endosomes for efficient transfection. Unlike viral 
vectors, non-viral vectors lack the protein machinery to destabilize the endosomal 
membrane. Therefore, the effect of various structural morphologies of lipoplexes to 
facilitate endosome escape is critical.  
As introduced above, the inclusion of helper lipids such as DOPE or cholesterol 
has been found to promote the gene transfection efficiency of lipoplexes.129-132 This 
result is mainly attributed to the neutral lipids’ ability to facilitate a phase transition in 
the lipoplex structure to non-bilayer structures, such as the HII phase. Using SAXS 
and optical microscopy, the HII morphology was observed in lipoplexes containing 
DOPE. DOPE has a negative natural curvature because of its larger volume of the 
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hydrophobic chains and smaller head group area. When incorporating DOPE into a 
cationic lipid DOTAP, the phase transition from L to HII occurs. The phase transition 
is known to catalyze the fusion of the lipoplexes with endosomal membranes, thus 
promoting the release of transgenes from endosomes.96, 101 Although inclusion of 
DOPE into lipoplexes can induce such a phase transition, it may also be triggered in 
endosomes by mixing with cellular lipids such as phosphatidylserine (PS).130 It has 
been suggested that ion pairing of negatively charged cellular lipids, such as PS, 
with cationic lipids in lipoplexes mediate the formation of HII lipoplexes, enhancing 
endosomal escape.133 In addition, PS itself also undergoes a L-HII phase transition 
under acidic conditions below pH4.134  
In addition to the presence of a helper lipid, the membrane charge density (m) 
also influences the destabilization of endosomal membrane. The membrane charge 
density is defined as the average charge per membrane area.135 Cationic liposomes 
typically consist of a mixture of cationic and neutral lipids, thus the membrane 
charge density may be manipulated by changing the molar fraction of neutral lipid or 
changing the head group charges of cationic lipid. The bilayers of lamellar lipoplexes 
are more stable when the complexes enter cells through endocytosis. Lin et al. think 
that the lamellar lipoplexes escaping from endosomes depend on their membrane 
charge density. Only those with a large enough membrane charge density may 
escape from endosomes through activated fusion with endosomal membrane 
lipids.136 Safinya and colleagues have shown that endosomal escape is the rate and 
efficiency limiting step for gene transfection with lamellar lipoplexes of low to 
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intermediate membrane charge density.135 Lamellar lipoplexes with an optimal 
membrane surface charge at (17.4 ± 0.2) x 10-3 e/Å achieved a comparable 
transfection efficiencies to that obtained from HII lipoplexes.
135 At the optimal 
membrane charge density regime 10-2< m <2 x 10
-2 e/Å, Caracciolo et al. studied 
the effect of multicomponent lipoplexes on transfection efficiency.137 Compared to 
binary lipoplexes, multicomponent systems consisting of several lipid components 
showed the superior transfection efficiency. This result may be mainly related to their 
higher fusogenicity and compatibility with endosomal membrane lipids.137 
Remarkably different from lamellar lipoplexes, the transfection efficiencies of 
hexagonal lipoplexes are independent of membrane charge density.136, 137 The 
difference in curvature between the outer endosomal monolayer (positive curvature) 
and the lipids coating DNA inside the complexes (negative curvature) is assumed to 
drive a rapid fusion of hexagonal lipoplexes with endosomal membrane, resulting in 
the release of DNA from the complexes.136  
1.3.4 Nuclear entry 
In order to achieve in successful gene transfection, transgenes must enter the 
nucleus and undergo transcription. Transgenes cannot passively diffuse through the 
nuclear membrane; this membrane, also called the nuclear envelope, is a major 
barrier to effective gene transfer. The nuclear envelope is a lipid double layer, and 
nuclear pores perforate it to form channels for the bidirectional shuttling of molecules 
between the nucleus and the cytoplasm.138 Generally, these channels have a limiting 
diameter of around 25 to 30 nm.139 It allows the passage of small molecules, but 
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large molecules require active transport through specific nuclear import proteins 
located in nuclear pores. 
To date, there are two mechanism proposed to explain how a transgene enters 
into the nucleus.81 The first one is passive entry into the nucleus of dividing cells. 
During cell mitosis, the nuclear envelope breaks down which facilitates transgene 
access to the nucleus. It has been shown that transfection efficiency is higher at or 
near cell mitosis than that obtained at quiescent cell phases.140, 141 The other 
mechanism for trangene entry into the nucleus of quiescent cells is an active 
transport of transgenes through the nuclear pores. It is well known that proteins 
bearing nuclear localization signals (NLSs) can bind to the nuclear envelope and be 
imported into the nucleus.138 The first NLS was identified from a SV40 T-antigen in 
1984.142 It has been evidenced that nuclear entry of plasmid DNA is dependent on 
whether the plasmid contains a SV40 sequence.143  
1.3.5 Summary 
Although cationic lipids have been studied for gene application since 1987, only 
7.6% of human gene delivery clinical trials have employed cationic lipid-based 
vectors.5 The biggest limitation is low transfection efficiency observed for cationic 
lipids. This limitation continues to drive research into alternatives to cationic lipids in 
the formulation of non-viral transfection vectors. One such alternative is a novel 
family of cationic surfactants, known as gemini surfactants. Compared to cationic 
lipids used in gene therapy, gemini surfactants can be synthesized from very 
inexpensive starting materials and on a laboratory scale, are easily prepared, are 
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able to dissolve in aqueous solution at room temperature, and are stable enough to 
be stored for months under room conditions. Thus, this new class of non-viral vector 
is cost effective, efficient, and very competitive for gene delivery. They will be 
discussed in detail below.    
1.4 Gemini surfactants   
Gemini surfactants are a class of surfactants made up of two surfactant monomers 
that are linked by a spacer group, as illustrated in Figure 1.5. The spacer group may 
be short (i.e., two methylene groups) or long (up to 20 or more methylene groups), 
hydrophobic or hydrophilic, and may contain other functional groups (i.e., pH 
sensitive amine groups). Similar to cationic lipids, gemini surfactants are amphiphilic 
molecules; however, compared to cationic lipids, gemini surfactants possess a 
higher charge per mass and have superior surface properties.144  
  
          
 
 
 
 
 
Figure 1.5 Scheme for gemini surfactant structure (left) and structure of the m-s-m 
gemini surfactant (right). 
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Compared to typical monomer surfactants, gemini surfactants demonstrate very 
unique properties and aggregation morphology. They can form aggregates at very 
low concentrations, and also demonstrate polymorphism (spherical micelles, 
cylindrical or bilayers, or inverted micelles).145 Critical micelle concentration (CMC, 
the concentration of surfactants above which micelles form.) values of gemini 
surfactants are one to two orders of magnitude lower than for the corresponding 
monomer surfactants,146 and they are much more efficient in lowering surface 
tension of water. They also show other enhanced features, such as low viscosity, 
better solubilizing properties, and stronger antimicrobial properties.146  
Because of their unique properties gemini surfactants have been well 
characterized by studying their solution properties, polymorphism behavior, and 
applications. Many of the synthesized cationic gemini surfactants are made of two 
alkyldimethyl-ammonium bromide moieties linked by a spacer with hydrophobic 
polymethylene groups, abbreviated m-s-m (see Figure 1.5); m is the number of 
carbon atoms in the alkyl tails and s represents the number of carbon atoms in the 
hydrophobic polymethylene spacer.44 Another widely studied class of dimeric 
surfactants are the sugar-based gemini surfactants; their head groups are made of 
reduced sugars, such as glucose and mannose, connected to tertiary amines or 
amides; and their spacer is usually polymethylene groups with different length.147 
The physico-chemical properties and micellar structures can be manipulated by 
varying the length of alkyl chains or spacer, degree of unsaturation of alkyl tails, and 
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symmetry or asymmetry of alkyl tails to rationally design better candidates for gene 
delivery.  
1.4.1 Molecular structure and properties of gemini surfactants 
The shape of aggregates formed by a gemini surfactant is influenced by its 
molecular structure. A popular theory used to predict the shape of micellar 
aggregates is that of the packing parameter (P) defined as:148 
        
where V is the volume of the alkyl tails, l is the length of alkyl chains, and a0 is the 
surface area occupied by the head group. The expected micellar aggregate shapes 
at different P values are listed in Table 1.4. For example, spherical micelles are 
expected when P is less than 0.33, which is generally seen for single-chained 
surfactants with relatively large head groups; vesicles or flexible bilayer structures 
are formed when P is in the range of 0.5-1, which can be observed for double-
chained surfactants with large head groups and flexible chains.  
Although the packing parameter can be used to predict the curvature of surfactant 
aggregates, the description of mesophases of surfactants in aqueous solution must 
also consider the arrangement of surfactant aggregates. In and Zana reviewed 
lyotropic mesophases in gemini surfactants-water mixtures.145 The lyotropic 
mesophases, illustrated in Figure 1.6, include the hexagonal phase (HI) which is 
made of spherical micelles packed on a hexagonal lattice, the inverted hexagonal 
phase (HII) which are made of inverted micelles arranged on a hexagonal lattice,  
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Table 1.4 Packing parameter and expected aggregate shape.149 
P Aggregate structure General surfactant type 
<0.33 Spherical micelles Single-chain surfactants with 
relatively large head groups 
0.33-0.5 Cylindrical or rod-shaped micelles Surfactants with relatively small 
head group 
0.5-1.0 Vesicles or flexible bilayer structure Double-chain surfactants with large 
head groups and flexible chains 
1.0 Planar bilayer structures Double-chain surfactants with small 
head groups or rigid chains 
>1.0 Inverted micelles Double-chain surfactants with small 
head groups, very bulky chains 
 
the lamellar phase (L) consisting of infinite bilayers separated by layers of water, 
and the cubic phase which is made either of spherical micelles arranged on a cubic 
lattice or of infinite layers of surfactants folded into a cubic bicontinuous structure. To 
lower the free energy of the mixture and optimize the distance between micelles, 
aggregate organization in water is spontaneous and driven by inter-micellar 
repulsion.150 From an energy minimization point of view, the most frequently 
observed mesophase is lamellar; with hexagonal and cubic phases being rarely 
found.151   
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Figure 1.6  Schematic pictures of lyotropic mesophases in surfactant-water mixtures. 
The normal hexagonal (HI), the lamellar (L), and the inverted hexagonal phases 
(HII) are illustrated by a, b, and c, respectively. The cubic phases are described by 
d.152  
Micelle shapes can be manipulated by changing the molecular structure of 
surfactants, such as the length of the spacer and the alkyl tails, the degree of 
asymmetry of the alkyl tails, and the type of head groups. For m-s-m type of 
surfactants, the literature shows that the effect of alkyl tail length on the aggregate 
shape is similar to that obtained with conventional surfactant monomers. An 
increase in the length of the alkyl tails results in a less curved micelle shape. Take a 
series of m-3-m (m = 10, 12, and 16) surfactants as an example. Spherical micelles 
were observed for m = 10; spherical micelles were formed at low concentrations for 
m = 12 and rod-shaped micelles at higher concentrations; and disklike micelles were 
observed for m = 16.146 Correspondingly, the effect of alkyl tail length on the 
mesophases of gemini surfactant-water mixtures has been examined. The phase 
behavior of m-6-m (m = 8, 10, and 12) mixing with water has also been reported.153 
With the increase of weight fraction of surfactant in their mixture with water, micelle 
phases as one-phase solution (A), a gel phase (B), a coagel phase (C), and mixture 
of a gel and a coagel phase (D), were obtained for 8-6-8; micelle phases at different 
a               
b                
c               d            
  37 
concentrations of 10-6-10 were A, B, and C; but for 12-6-12, in addition to A, B, C, 
and D, the presence of hydrated surfactant crystals with the surfactant solution was 
observed. These results indicate that micelle characteristics change with the 
variation of alkyl tail length.  
The effect of the spacer group on aggregate shape has also been investigated. 
Threadlike micelles were observed for the 12-2-12 surfactant at a concentration of 2 
wt% and the 12-3-12 surfactant at a concentration of 7 wt%;154 spherical micelle 
aggregates were formed for the 12-s-12 (4 < s ≤ 12) surfactants; at s ≥ 14, vesicles 
were observed.154 In contrast, the 16-s-16 surfactants show a more complex 
behavior. A mixture of vesicles, bilayer fragments, and disk-like micelles were 
revealed for 16-3-16 by Cryo-TEM; disk-like micelles for 16-4-16 were observed; and 
spherical micelles were shown for 16-8-16.154 Additionally, spherical micelles were 
observed in the16-12-16 using small angle neutron scattering (SANS).155  The 
aggregate morphology has not been investigated for 16-s-16 surfactants with s 
greater than 12.  
In terms of packing parameter, the 12-2-12 has a P above 0.33 and elongated 
micelles should be formed, in agreement with experimental results.146 Head group 
area increases rapidly for m-s-m surfactants with s ≤ 8 at the micelle surface, while 
the volume and length of the alkyl tails change little. Thus, P decreases with 
increasing s (s ≤ 8), corresponding to a change from elongated micelles to spherical 
micelles, also as has been observed experimentally.156 Because of increasing 
hydrophobicity, the longer spacers (s > 10) fold into hydrophobic micelle core, 
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leading to an increase of volume of alkyl tails and decrease of head group area. This 
results in a rapid increase of packing parameter and the formation of less curved 
aggregates, such as vesicles. This is also revealed by Cryo-TEM images.156 
The aggregate properties of sugar-based gemini surfactants have been 
determined by Engberts and colleagues.147 The head group area is considered as a 
decisive parameter that influences the packing parameter. The head group having 
tertiary amines is pH-sensitive, for which the packing parameter decreases with a 
decrease in pH. At lower pH, more gemini surfactants become protonated and the 
head group area becomes larger due to increased electrostatic repulsion between 
the head groups. Thus, the aggregate shape changes to a more curved structure, 
from vesicles to spherical micelles.147 This protonation-driven vesicle-to-micelle 
transition was observed only for those sugar-based gemini surfactants containing an 
amine linkage.147 If the head group contains an amide group instead of amine, 
protonation of the head group does not occur, and no change in aggregate structure 
with pH is observed.   
In addition to aggregate structure, another property influenced by the molecular 
structure of gemini surfactants is their CMC values. The effect of variations to the 
alkyl tails on the CMC of a gemini surfactant is similar to that observed for traditional, 
monomeric surfactants. The CMC values decrease with an increase in the alkyl tail 
length because of the corresponding increase in hydrophobicity. The linear 
relationship of log CMC as a function of the alkyl tail length is observed for most 
surfactants, including conventional surfactants (one head with one tail), bolaform 
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surfactants (one head with two tails), and gemini surfactants (two heads with two 
tails).157   
CMC values can be manipulated by introducing asymmetric hydrocarbon tails as 
well. The most investigated asymmetric gemini surfactants are m-s-n type with two 
alkyl tails of different carbon numbers. The CMC values of 12-2-12, 14-2-10, and 16-
2-8 (which have the same spacer within the molecular structure) were reported to be 
0.96, 0.95, and 0.75 mM, respectively.158 Although the overall length (m + n = 24) of 
the tails and the spacer were kept constant, the dissymmetry of those surfactants 
influenced their CMC values. Bai et al. investigated a type of gemini surfactants, m-
6-n, with m + n = 24 and m = 12, 13, 14, 16, and 18.159 The CMC values decreased 
linearly with an increase in the m/n ratios. From a thermodynamic point of view, the 
increase of assymmetry showed a more negative micellization enthalpy, indicating a 
larger effective hydrophobicity caused by the addition of a CH2 group to the long 
alkyl tail than that of adding a CH2 group to the short tail.
159 Thus, the increase of 
dissymmetry actually results in the increased hydrophobicity of surfactants.  
Compared to conventional surfactants, the nature and structure of a spacer group 
are critical factors that give rise to the unique properties of the gemini surfactant. 
CMC values are influenced by the length of spacer group. For the 12-s-12 gemini 
surfactants, in the plot of log CMC as a function of spacer length (Figure 1.7), the 
CMC values reached a maximum when s is 5 or 6, then nonlinearly decreased with 
the increase of the spacer length in the range of 5 < s < 10, and linearly decreased 
for s ≥ 10.157 It is believed that the conformational change of spacer and the resulting 
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effect on head group hydration and alkyl tail orientation resulted in the maximum of 
CMC at s = 5 or 6.160 At higher s, the spacer is long enough to be part of the micelle 
hydrophobic core, leading to the decreased CMC. 
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Figure 1.7 The CMC values as a function of the number of carbon atoms in the 
spacer of 12-s-12 (2 ≤ s ≤ 16). Adapted from Zana et al..157 
The effect of substitution within the spacer group on the CMC is complex, and 
depends upon the nature of the substituents.  For hydrophilic oxyethylene (EO) 
substituted spacers, an increase in the number of EO groups within the spacer (also 
corresponding to an increase in spacer length) results in an increase in the CMC of 
12-2(EO)x-12 (x=1, 2, and 3), which is contrary to the observation from the 12-s-12 
gemini surfactants. This is possibly because of the increased solubility of 12-2(EO)x-
12 surfactants and the decreased hydrophobicity between tails due to the steric 
effect caused by EO groups.161, 162 Compared to 12-4-12, the hydroxyl substituted 
(12-4(OH)n-12) surfactants showed the decreased CMC values with increasing the 
number of hydroxyl group in the spacer. This is because the -OH group(s) form 
hydrogen bonds with water molecules, thus facilitating the location of the spacer 
toward the aqueous phase to form micelles.163-165 The addition of an amine 
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functional group to the spacer of the gemini surfactants has been recently reported 
by Wettig et al..166 Compared to 12-2(EO)x-12 (x=1, 2, and 3), the gemini surfactants 
having N-CH3 in the spacer, 12-5N-12, 12-8N-12, and 12-7N-12, are more 
hydrophobic. However, these compounds with N-CH3 substituent showed higher 
CMC values. This increase is likely attributed to the increased steric repulsion and 
correlated packing at the micelle-water interface. Changes in chemical structure of 
the spacer have also been studied to determine the influence on aggregation 
properties of the gemini surfactants. For example, three gemini surfactants, 12-
2(EO)-12, 12-6-12, and 12-xylyl-12, having the same head groups, C12 tails, and 
approximately the same length of spacer, have been reported that the spacer nature 
influenced their aggregation properties.167 As expected, 12-2(EO)-12 showed the 
lowest CMC due to the formation of hydrogen bonds with water. 12-xylyl-12 having a 
hydrophobic and rigid ring within the spacer showed the largest CMC value, 
indicating that it is difficult to incorporate such a spacer into the hydrophilic region of 
micelles.  
1.4.2  Interaction between cationic gemini surfactants and DNA  
The interaction of gemini surfactants with DNA triggers a new research area in which 
gemini surfactants have been widely studied as gene delivery vectors for gene 
therapy.168 Because of their low cost, efficient binding with and compaction of 
DNA,169 the use of cationic gemini surfactants as gene delivery vectors has become 
an attractive research area for the past two decades. Because of the large variation 
of aggregate structures that can be accessed through simple modifications of the 
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molecular structure of the gemini surfactants, it should be possible to more easily 
optimize DNA delivery efficiencies by taking advantage of changes in uptake 
mechanism and endosomal escape without substantially impacting on the factors 
such as formulation and toxicity.   
1.4.2.1 Effect of length and nature of alkyl tails  
With an increase in alkyl tail length, hydrophobic interactions between surfactant 
molecules increases, resulting in more efficient compaction with DNA molecules.170 
Dias et al. examined the interaction between DNA and cationic surfactants with 
different tail length, cetyl trimethyl ammonium bromide (C19H42BrN, CTAB), 
tetradecyl trimethyl ammonium bromide (C17H38BrN, TTAB), and dodecyl trimethyl 
ammonium bromide (C15H34BrN, DTAB).
171 CTAB was shown to bind DNA more 
strongly due to its longer alkyl tail. This study indicates the importance of the 
hydrophobicity of the surfactant molecules to DNA binding process. Furthermore, the 
authors performed SAXS studies to evaluate the structure of the DNA with CTAB, 
TTAB, and DTAB, respectively.170 Both CTAB and TTAB showed inverted hexagonal 
diffraction peaks with different lattice spacing of 54.4 and 53.1 , respectively. It is 
known that CTAB and TTAB prefer to form rod-shaped micelles with an increase in 
ionic strength in water, and the addition of DNA is believed to have a similar 
effect.170 Compared to CTAB and TTAB, DTAB has a smaller packing parameter 
because of the shorter hydrophobic chain length. This results in more curved 
spherical micelles formed.170  
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Similar results have been observed with gemini surfactants. The effect of alkyl tail 
length on cationic gemini surfactants-DNA structure has been investigated using m-
4-m (m = 12, 13, 14, and 16) gemini surfactants and calf thymus DNA.172 The SAXS 
profiles revealed that for m = 12, 13, and 14, the gemini surfactants-DNA complexes 
were packed in a hexagonal lattice at 25 °C, but more gemini surfactant was 
required for those with the shorter alkyl tail length; while for 16-4-16, two scattering 
peaks corresponding neither to the lamellar nor the hexagonal phase were observed 
for the 16-4-16-DNA complexes at 25 °C. These results indicate that the length of 
alkyl tails of gemini surfactants has an effect on structures of surfactant-DNA 
complexes. 
Additionally, it has been reported that the condensation of DNA can be improved 
by increasing asymmetric extent of gemini surfactants. For m-s-n type of gemini 
surfactants with different length of saturated hydrocarbon tails, the hydrophobic 
interaction among asymmetric gemini surfactant molecules is believed to be stronger 
with increasing the assymmetry degree. However, the addition of DNA disrupts the 
hydrophobic interaction among the surfactant molecules due to the electrostatic 
attractive interaction between the head groups of gemini surfactants and DNA 
backbones. With an increased degree of dissymmetry, the interaction of the m-6-n 
(m + n = 24, and m = 12,14, 16, and 18) surfactants with DNA was examined by 
ITC.173 The results show that the dissymmetry degree (m/n) dramatically influences 
the interaction of the m-6-n with DNA. The critical aggregation concentration (CAC, 
specifically representing the concentration at which micelle aggregates begin to form 
  44 
along the DNA molecule.168) and saturation concentration (C2, defined as the 
concentration at which any added surfactant does not interact with the DNA 
molecules.168) decreased with increased dissymmetry. The enthalpy change (ΔH) 
and Gibbs free energy change (ΔG) for the aggregation process were more negative 
with increased m/n, representing that the hydrophobic interaction between the 
hydrophobic tails of the surfactants increases and the aggregation process is more 
spontaneous. The Gibbs free energy change (ΔG) for the interaction between the 
gemini surfactants and DNA was negative, but increased with the increased m/n, 
indicating that the interaction of the m-6-n surfactants with DNA is weaker.  
In addition to the effect caused by changing alkyl tail length, molecular structure of 
alkyl tails also influences the interaction of gemini surfactants with DNA. Two gemini 
surfactants containing pyrenyl groups in one of the alkyl chains of the surfactants 
(pyr-3-12 and pyr-6-12) were synthesized by Wang et al.174 and the binding 
interaction between pyrenyl-substituted gemini surfactants and salmon sperm DNA 
was examined by Wettig et al..175 Compared to the 12-s-12 surfactants with DNA, 
the enthalprograms obtained from ITC measurements for the pyr-s-12 (s = 3 and 6) 
showed a significant difference. The enthalpy profiles obtained from 12-s-12 (s = 3 
and 6) with DNA have shown that the binding process occurs in three steps: an 
initial step of interactions between DNA and gemini surfactant micelles, the 
formation of large aggregates, and finally precipitation of a neutral complex occurring 
at the addition of DNA. Similar to the 12-s-12 (s = 3 and 6), the initial binding of the 
pyr-s-12 (s = 3 and 6) resulted in the formation of “beads on a string complex”;174 
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different from the 12-s-12, the complexes formed by pyr-s-12 (s = 3 and 6) in the 
presence of DNA do not precipitate in the formation of flocs because the pyrenyl 
groups can be intercalated between DNA base pairs. 
1.4.2.2 Effect of spacer length 
The compaction of bacteriophage T4 DNA by the 12-s-12 (2 ≤ s ≤ 10) gemini 
surfactants has been reported by Karlsson and colleagues.176 It was found that the 
12-s-12 surfactants with shorter spacers (s ≤ 3) showed more efficient compaction of 
the DNA, while those surfactants with intermediate length (s =5-10) were less 
efficient. The results of a circular dichroism (CD) study show that cationic gemini 
surfactants induce a structural transition of DNA from a native B-form (right-handed 
secondary DNA conformation177) to a tertiary  phase (left-handed DNA 
conformation177).178 The study regarding spacer length of the 12-s-12 on DNA phase 
structure found that the 12-s-12 surfactants with shorter (s < 4) or longer (s > 10) 
spacers were more efficient in inducing the tightly packed  phase.179 A recent study 
also shows that the spacer length has a great effect on the properties of the complex 
structures. At s ≤ 6, CD signal indicates that 18-s-18 surfactants induce a structural 
change of DNA from the double-stranded helix to a tertiary ᴪ phase.180  
In addition to changes in DNA phase, molecular areas of gemini surfactant-DNA 
complex monolayers have been reported to change with spacer length. The 
molecular areas of the 12-s-12-DNA complex monolayers reached a maximum at s 
= 6, and then decreased as the number of methylene groups increases.181 
Furthermore, atomic force microscopy (AFM) images revealed the effect of the 
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spacer length on the 12-s-12-DNA complex morphologies. The width of the fiber-like 
structures and the distance between these structures were related to the spacer 
length of the gemini surfactants.181  
1.4.2.3 Summary 
As introduced above, molecular structure of gemini surfactants plays an important 
role in the interaction with DNA, which then gives rise to different structural 
properties of gemini surfactant-DNA complexes. This is very important for gemini 
surfactants used as a novel class of gene delivery vectors. Structural changes of 
resultant gemini surfactant-DNA complexes can be achieved by manipulating the 
length or nature of alkyl tails and spacer of gemini surfactants. Therefore, a rational 
design based on such information can produce more efficient gemini surfactants for 
gene delivery.    
1.4.3 Gemini surfactants and gene transfection 
To date, gemini surfactants widely studied for gene delivery include sugar-based 
gemini surfactants, peptide-based gemini surfactants, and m-s-m surfactants.168 In 
this section, the first two types will be briefly introduced and the third one will be 
discussed in greater detail because the gemini surfactants involved in this thesis 
project are closely related to the m-s-m surfactants. 
1.4.3.1 Peptide-based gemini surfactants 
Peptide-based gemini surfactants contain head groups derived from positively 
charged amino acids and/or amine-linked carbohydrates (Table 1.5). This type of 
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gemini surfactant has been synthesized and studied widely by the European 
Network on Gemini Surfactants (ENGEMS) group. In general, higher transfection 
efficiency has been observed in the peptide-based surfactants, depending on the 
length of the alkyl tails, the peptide sequence used, and the manner in which the 
peptide sequences interacted with the backbone of the compounds.182 There are 
general observations summarized by Wettig et al.: the length of peptide localization 
sequence for spermine-based gemini compounds did not show any difference; for 
cystine dimer-based gemini compounds, the use of lysine as the -amino acid to the 
spacer (a disulfide bond) showed a higher transfection efficiency than that of 
histidine or arginine; the greatest transfection activity was achieved using cystine 
dimer-based compounds having triamino acid peptide residues and linkages where 
lysine residues were coupled with the side-chain -amino acid groups; for the 
peptide-based compounds, oleyl chains usually showed a higher efficiency than did 
saturated alkyl chains.168 
1.4.3.2 Sugar based gemini surfactants 
Sugar-based gemini surfactants consist of glucose or mannose head groups which 
connect to a spacer through an amide or amine linker group (Table 1.5). The 
transfection activity of this type of gemini surfactants was examined in Chinese 
hamster ovary (CHO)-K1 cells. The results showed that  
 the mannose head group was more efficient than the glucose;  
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Table 1.5 Molecular structures of peptide-based and sugar-based gemini surfactants 
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 spacer with EO-substitutions were more efficient and less toxic than those 
without EO substitution;182  
 introduction of double bonds in the alkyl chains enhanced the transfection 
efficiency;183  
 and the presence of an amine-based linker improved transfection efficiency 
compared to an amide-based linker.184  
Using SAXS and Cryo-TEM, the structure of the complexes formed by DNA with 
glucose-based gemini surfactants with 9-octadecenyl chains has been investigated 
in the pH range of 3.0-8.8.184 Three morphologies of complexes were observed at 
different pHs: lamellar phase, condensed lamellar phase, and inverted hexagonal 
phase. The complexes showed a phase transition from the lamellar to the inverted 
hexagonal at an endosomal pH, which is hypothesized to be a dominant reason for 
its pronounced transfection activity. Bell et al. proposed key features for the rational 
design of efficient glucose-based gemini surfactants for gene delivery such as  
 a spacer with six methylene groups,  
 the presence of a head group containing tertiary amine groups that can 
experience a protonation at the physiological pH range and induce the 
formation of HII in endosomes,  
 unsaturated alkyl chains. 
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Wasungu et al. reported that the improved gene transfection was mediated by pH-
sensitive sugar-based gemini surfactants in CHO cells and in vivo.185 The 
surfactants can efficiently transfect CHO cells in vitro. This may be correlated with 
the observation that the complexes formed by this type of surfactants and DNA at 
physiological pH exhibited a lamellar phase, but exhibited a HII morphology in 
endosomes. Two compounds among these surfactants were further investigated in 
male nude mice and they demonstrated in vivo transfection using a bioluminescence 
assay.   
1.4.3.3 M-s-m gemini surfactants and their derivatives for gene transfection  
Inspired by the mixture of dimethyldioctadecyl ammonium bromide and DOPE (trade 
marked as Lipofectin® and marketed by Life Technology), as a gene transfection 
vector, Rosenzweig and colleagues synthesized 16-s-16 (s=2, 3, and 6) and 18:1-s-
18:1 (s=2, 3, and 6) surfactants and investigated their transfection activity in baby 
hamster kidney (BHK) cells using a -galactosidase assay.186 The results showed 
that the saturated derivatives with a six-methylene spacer, and the unsaturated 
derivatives with both three- and six-methylene spacers, were the most efficient 
agents for the gene transfection; the addition of DOPE to the 16-2-16 at different 
mole ratios decreased the transfection efficiency compared to the one without 
DOPE; The transfection efficiency was dramatically inhibited in the presence of 10% 
serum. The authors hypothesized that the different hydration behavior dominated by 
the saturated and the unsaturated derivatives resulted in the different transfection 
activity.  
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In order to improve gene transfection efficiency, a number of m-s-m type gemini 
surfactants have been synthesized and examined since Rosenzweig’s work. The 
effect of alkyl tail length on transfection activity has been examined. Badea 
investigated the transfection activity of m-3-m (m=12 and 16) and 18:1-3-18:1 
surfactants and found that the expression of IFN- in PAM 212 cells increased with 
alkyl tail length; the highest IFN- was observed for gemini surfactants with oleyl 
tails. Additionally, the incorporation of DOPE significantly improved the gene 
expression in PAM 212 cells.179  
Meanwhile, the influence of spacer nature and length on gene transfection has 
also been studied. The 12-s-12 (3 ≤ s ≤ 16) was examined in PAM 212 cells using 
the pGTmCMV.IFN-GFP plasmid.187, 188 The transfection efficiency was found to be 
related to the length of the spacer (the data is plotted in Figure 1.8); the 12-3-12 
surfactant showed the highest transfection efficiency; and the minimum expression 
of IFN- was observed at s = 8. It is believed that the distance between head groups 
in the gemini surfactants with shorter spacer (s ≤ 4) is close to the distance between 
two phosphate groups in DNA molecules, resulting in stronger complexation of the 
gemini surfactant and DNA.168 The longer spacer (s ≥ 12) was believed to bend into 
the hydrophobic core formed by the alkyl tails, which decreases the distance 
between the head groups, resulting in the increase of the transfection efficiency for 
long spacers. Although Dauty et al. think that a high CMC is preferable to surfactant-
DNA complex formation and a low CMC value may improve the stability of the 
complexes,189 no correlation was observed between the CMC values of 12-s-12 and 
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transfection efficiency.190 Wettig and colleagues believe that the enhanced 
transfection observed for the 12-s-12 with longer spacers most likely results from a 
bilayer membrane disruption effect caused by the folding of the longer spacers into 
the alkyl tails of a membrane.168 
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Figure 1.8 Effect of 12-s-12 (s = 3, 4, 6, 8, 10, 12, and 16) on the transfection of 
PAM 212 cells with pGTmCMV.IFN-GFP plasmid. Adapted from Badea et al..187  
Transfection activity of the m-s-m type of gemini surfactants containing ethylene 
oxide, hydroxyl groups, or methoxy groups in their spacers has been studied. The 
mono-, di-, and tri-ethylene oxide substituted derivatives of the 12-s-12 compounds 
have been examined by Wettig et al.168 The results showed that the transfection did 
not significantly change with addition of one or more ethylene oxide repeat units. A 
single hydroxyl group incorporated to the spacer of 12-4-12 was observed to 
increase transfection efficiency four times higher than that obtained with 12-4-12; the 
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addition of two hydroxyl groups in the spacer did not show the same level of 
enhancement. The methoxy-substituted derivatives of 16-4-16 were examined in 
COS7, LA7 (rat mammary adenocarcinoma cell line), and human fibroblast cells.178 
The highest efficiency was observed for the 2R,3S-16-4(OCH3)2-16, followed by 16-
4-16, and finally 2S,3S-16-4(OCH3)2-16. The authors proposed that the 
rearrangement of charged phosphate and nitrogen ions in the bilayer resulted in the 
enhanced transfection. In fact, the stereochemistry of the compounds may be 
important when it is involved in the targeting to the cell surface receptors.191, 192   
In addition to the modification in the spacer introduced above, Wettig et al. 
investigated the transfection of the 12-s-12 series gemini surfactants with modified 
spacers ((N-CH3) and (N-H)- substitutes, seen in Figure 1.9) in COS7 cells using a 
pMASIA.Luc plasmid.193 It was expected that the modified spacer would enhance 
the gene transfection. The results have shown that the N-CH3 substituted gemini 
surfactants (12-5N-12, 12-7N-12, and 12-8N-12) do enhance the luciferase 
expression in COS7 cells; however, the N-H substituted 12-7NH-12 was the even 
more efficient. A structural analysis on the spacing between the nitrogen centers 
suggests that the trimethylene spacing between nitrogen centers in the 12-7N-12 
and 12-7NH-12 surfactants is closer to the “optimal” spacing which facilitates DNA 
compaction. The lower transfection observed for the 12-5N-12 and 12-8N-12 
compounds may be caused by a less than optimal two-methylene unit spacing 
between nitrogen centers. The highest luciferase expression achieved by the 12-
7NH-12 is also believed to be correlated to pH-dependent morphology change under 
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acidic conditions, which may enhance fusion with endosomal membranes and 
facilitate DNA release from the endosomes.193, 194  
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Figure 1.9 Chemical structures of 12-s-12 with nitrogen-substituted spacers.193  
As introduced above, changes in molecular structure of gemini surfactants have 
an effect on their transfection activity. It has been proposed that high transfection 
efficiency is correlated to the ability of a delivery system to adopt polymorphic phase 
structures. Koltover et al. found that lamellar complexes bind strongly to anionic 
membrane lipids (model of cellular lipids), while the inverted hexagonal complexes 
are unstable and rapidly fuse with membrane lipids, resulting in rapid release of DNA 
and higher transfection efficiency.96 A highly efficient vector, SAINT (see the 
structure in Figure 1.4), was investigated to examine the relationship of the 
polymorphism of SAINT/DOPE-DNA complexes to gene transfection. The results 
show that increased gene transfection efficiency is observed for the complexes 
displaying hexagonal morphologies, whereas the lamellar morphology strongly 
reduces transfection efficiency. It was concluded that for DOPE-containing 
complexes, the molecular structure and the nonbilayer preferences of the cationic 
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lipid control the phase structure(s) of the lipoplexes and thereby the transfection 
efficiency.131 Wettig et al. compared the phase structures of complexes formed by 
DNA, m-s-m (m=12, 16, and 18:1; s=2, 3, and 4) compounds, and DOPE using 
SAXS.168 It has been found that compounds having shorter spacers formed a 
mixture of lamellar and cubic structures. Compared to the unsubstituted compound, 
the amine-substituted 12-7NH-12 delivery system showed a lamellar morphology, as 
well as other hypothesized to be cubic phases; such compounds showed 
significantly higher transfection efficiencies.193  
1.4.3.4 Summary 
As introduced above, it is very important that gemini surfactants can efficiently 
compact with DNA and adopt a flexible phase structure for effective cellular uptake 
and endosomal release. Many factors influence DNA compaction and the structure 
of surfactant-DNA complexes. One of the factors is the molecular structure of the 
gemini surfactants. Variations on molecular structures of gemini surfactants have 
been shown to influence their interaction with DNA and the resulting phase 
structures of surfactant–DNA complexes. Such studies regarding the molecular 
properties of gemini surfactants, interaction of surfactants and DNA, and structural 
activity of gemini surfactants in gene transfection provide a valuable background for 
rational design of new gemini surfactants as novel candidates for gene delivery. 
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Chapter 2 Hypothesis and Objectives 
2.1 Basis for rational design of novel gemini surfactants 
Rational design is a strategy to develop new molecules with specific functionality, 
based on the ability to predict how the new molecules will influence their activity 
through the modified structures. The rational design of novel gemini surfactants can 
be done based on observations reported in literature. Firstly, a pH-sensitive group 
has been introduced into gemini surfactants. Sugar-based gemini surfactants with 
the amine functional groups in the head groups have shown pH-dependent 
aggregation behavior. 147, 195 Vesicles are formed near neutral pH which were 
observed to transform into cylindrical or wormlike micelles at pH<5.5. Aggregates 
stability was also related to aqueous pH with positively charged vesicles having 
good stability at pH < 7; but become unstable and sediment out from the solution 
when close to neutral pH. By counting GFP-positive cells from the total survival cells, 
the pH-sensitive sugar-based gemini surfactants achieved around 70% GFP 
expression in CHO cells. In vivo studies exhibited a prolonged stability in salt and 
serum.185 Similarly, the incorporation of a pH-sensitive secondary amine substitute in 
the spacer group of the basic m-s-m gemini surfactants led to 9-fold increase of 
transfection efficiency compared to an unsubstituted gemini surfactant. 
Correspondingly, pH dependent behavior of the complexes was observed, such as a 
transition in size and zeta potential occurring at pH 5.5, and multiple phase 
structures formed from the mixture of 12-7NH-12, DNA, and DOPE, which are 
absent when the 12-7N-12 is used instead of 12-7NH-12.193 Although the 
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mechanism of pH-sensitive gemini surfactants for improving transfection efficiency 
has not been fully investigated, it is certain that pH-sensitive substitutes incorporated 
into gemini surfactants can influence the aggregation behavior and structure of the 
complexes formed by the gemini surfactant and DNA with/without a neutral lipid, 
thus affecting gene transfection efficiency.  
Secondly, surfactants with unsaturated hydrocarbon chains have shown unique 
aggregate morphologies and higher transfection efficiency. Gemini surfactants with 
oleyl tails showed highest IFN-y expression in PAM 212 cells.193 The glucose-based 
gemini surfactant with oleyl chains demonstrated more effective transfection 
efficiency than the saturated analogue. Unsaturated chains are believed to increase 
the structural flexibility of the complex formed by the gemini surfactants and DNA, 
which facilitates endosomal fusion and release of the transgene materials.184 
Additionally, surfactants with bulky hydrocarbon chains showed structural flexibility in 
terms of exhibiting cubic or inverted hexagonal phase structures. It has been 
reported that glycerate surfactants with oleyl, or hexahydrofarnesyl (3,7,11-trimethyl-
dodecyl), or phytanyl (3,7,11,15-tetramethyl-hexadecyl) tails, exhibited cubic or 
inverted hexagonal phases at the interface with water.196 Compared to conventional 
phospholipids, phytanyl-chained phospholipids showed unique characteristics, such 
as reduced permeability and higher salt tolerance.197 These early studies provide a 
good background for the design of novel gemini surfactants with unsaturated and/or 
bulky alkyl tails (i.e., phytanyl substituted tails).  
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To rationally design and develop more efficient gemini surfactants, a few other 
general observations for the m-s-m type of compounds are made as follows. 
 Compounds with longer alkyl chains (C16 or C18) show higher transfection 
efficiency.179, 194  
 Compounds containing a shorter spacer (≤ 4) achieve higher transfection 
activity.193 The spacer has an effect on interactions between nitrogen 
groups of the gemini surfactants and the DNA phosphate groups; compared 
to dimethylene or longer spacing, the trimethylene spacing is believed to 
provide a closer match for the electrostatic interaction with phosphate 
groups of the DNA. 
 Most literature shows the addition of a neutral lipid to gemini surfactant-
DNA complexes enhances transfection efficiency; DOPE is the most widely 
used neutral lipid so far.188, 190, 193, 194  
 Gemini surfactants that prefer to form non-bilayer structures (such as the 
inverted hexagonal or cubic) are more effective than those forming lamellar 
morphologies.168, 193 
2.2 Hypothesis 
Based on literature regarding non-viral vectors for gene therapy and research 
progress in our laboratory, the rational design of novel gemini surfactants should 
incorporate the following. 
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1) Asymmetric hydrocarbon tails of gemini surfactants expected to increase 
the phase flexibility of the complexes formed by the gemini surfactants, 
DNA, and a neutral lipid. This will result in the formation of flexible phase 
structures within the complexes, facilitating endosomal fusion. 
2) A pH-sensitive group incorporated into the spacer group. The protonation    
of the pH-sensitive group under endosomal conditions should result in a 
change in the phase structure of the complexes, leading to enhanced 
membrane fusion and/or osmotic swelling and rupture of the endosomal 
membrane due to enhanced endosomal Cl- accumulation caused by 
“proton-sponge mechanism”. 
3) Three-methylene unit spacing between nitrogen centers. It has been  
proposed that the distance between ammonium head groups of the 
gemini surfactants with a spacer less than 4 is close to the distance 
between two phosphate groups in DNA molecules, which results in 
stronger complexation of the gemini surfactants and DNA.   
Given the above, it is hypothesized that asymmetric phytanyl-chained gemini 
surfactants having a shorter spacer and/or secondary amine within the spacer 
will improve gene transfection efficiency. The enhancement may be attributed to 
their ability to adopt flexible phase structures and/or induce pH-sensitive phase 
transition(s) that facilitate endosomal escape.  
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2.3 Objectives 
The overall objective of the project is to design, synthesize, and characterize 
asymmetric gemini surfactants-based transfection vectors for use in ovarian cancer 
gene therapy. Specific objectives are detailed below. 
1) Synthesize and characterize the asymmetric phytanyl substituted gemini 
surfactants: phy-3-m and phy-7NH-m (m=12, 16, and 18). Molecular 
structures of the surfactants are shown in Table 2.1.  
2) Determine In vitro transfection efficiencies for the phytanyl substituted gemini 
surfactants as vectors for ovarian cancer gene therapy. 
3) Characterize the complexes formed by the phytanyl substituted gemini 
surfactants, DNA, and DOPE, by measuring particle size and zeta potential. 
4) Investigation of the transfection complexes phase structures using SAXS.  
The results and discussion regarding the first objective will be detailed in Chapter 3. 
Chapter 4 outlines the results and discussion about the objectives 2, 3, and 4.  
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Table 2.1 Gemini surfactants used in the project. 
Code name Chemical structure 
 
Phy-3-m 
m=12, 16, and 18 
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Chapter 3  Synthesis and characterization of phytanyl substituted 
gemini surfactants for gene delivery  
3.1 Introduction 
The focus of this project is to rationally design and develop novel gemini surfactants 
for use as improved gene delivery vectors. As introduced in Chapter 1, the nature 
and length of spacer group influences gene transfection efficiencies; however, little 
work has been carried out that investigates the effect of changes in the hydrophobic 
volume of the alkyl tails though studies on variations in the length of alkyl tail have 
been reported. The increased hydrophobic volume of the alkyl tails may give rise to 
a larger packing parameter (P), indicative of such surfactants adopting the inverted 
hexagonal and/or cubic phases. This could result in enhanced transgene activity.  
In this work, a series of phytanyl-substituted gemini surfactants were designed and 
synthesized. The aggregation properties of these surfactants were studied using 
surface tension, specific conductance, particle size, and transmission electron 
microscopy techniques. The objective of this study was to investigate the effect of 
phytanyl groups as the alkyl tails on the micelle aggregation properties of the gemini 
surfactants compared to their corresponding symmetric gemini surfactants as a part 
of our efforts to design gemini surfactants that are more efficient transgene delivery 
vectors than the cationic lipids and surfactants currently in use for transgene 
delivery.  
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3.2 Methods and Materials 
All gemini surfactants used in this project were synthesized in our laboratory. The 
symmetric m-3-m (m = 12, 16, and 18) was synthesized using the method from 
Wettig and Verrall.44  
3.2.1 Synthesis of phytanyl bromide 
Phytanyl bromide is one of starting reagents for the synthesis of phy-3-m and phy-
7NH-m (m=12, 16, and 18). The synthesis of phytanyl bromide was carried out 
according to the method of Bendavid et al.198 Briefly, the first step is the 
hydrogenation of phytol over Raney nickel to produce phytanol; the second step is to 
expose phytanol to hydrogen bromide acid to give phytanyl bromide (Scheme 3.1). 
The method to produce phytanyl bromide is described as following. Phytol (Acros 
Organics, 10.0 g) in 50 mL of ethanol was reduced under hydrogen at atmospheric 
pressure over Raney nickel (2 g, Aldrich) for 3 days. The catalyst was removed by 
filtration through Celite and the filtrate concentrated under reduced pressure to give 
phytanol (95%). Next, concentrated sulfuric acid (Aldrich, 98%, 10 mL) was added 
slowly over 2 minutes to a solution of 48% hydrobromic acid (Fluka, 100mL). 
Phytanol (9.5 g, 0.032 mol) was added to the above mixture, and the mixture was 
refluxed for 6 h. After cooling to room temperature, the mixture was extracted with 
diethyl ether (2 x 60 mL), and the combined ether layers were washed with 10% 
NaHCO3 in water (3 x 40 mL). The combined aqueous layers were extracted with 
diethyl ether (2 x 36 mL), and the combined ether layers were washed with saturated 
NaCl (3 x 40 mL). The ether layer was dried by adding anhydrous Na2SO4 (20 g) 
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and concentrated by rotary evaporation. The crude product was distilled under 
vacuum (130-140 °C/0.4 mmHg) to give pure phytanyl bromide (9.2 g, 0.026 mol, 
80%). The purified product was characterized by 1H NMR. The NMR data is given in 
Appendix A. 
 
Scheme 3.1 Synthesis of phytanyl bromide. i. H2, RaNi, EtOH, 3 days; ii.H2SO4 
(98%), HBr (48%), reflux for 6 h. 
3.2.2 Synthesis of phy-3-m (m = 12, 16, and 18) 
The synthesis of phy-3-m was carried out according to the method from Wang et al., 
which was used to prepare pyrenyl-modified gemini surfactants.174 Phytanyl bromide 
(1.09 g, 3.02 mmol) was added to N,N,N’,N’-tetramethyl-1,3-propane-diamine 
(Aldrich, 0.489 g, 3.75 mmol) in 30 mL of anhydrous acetontrile. The mixture was 
stirred at 50 °C for 3 days. The solvent was reduced under vacuum to approximately 
1 mL. The mixture was transferred to another round bottom flask to which 1-
bromododecane (Acros Organics), 1-bromohexadecane (Acros Organics), or 1-
bromooctadecane (Acros Organics) was added with 10 mL of acetone and refluxed 
for 2 days. The crude product was recrystallized from anhydrous acetonitrile and 
produced a final product (phy-3-12, phy-3-16, and phy-3-18), respectively; (Scheme 
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3.2). The purified products were characterized by 1H NMR and mass spectroscopy 
(MS). The NMR and MS data is given in Appendix A and B, respectively. 
 
 
Scheme 3.2 Synthesis of phy-3-m (m = 12, 16, and 18). i. CNCH3, 50°C, 3 days; ii. 
RBr (R = C12H25 or C16H33 or C18H37), CNCH3, reflux, 2 days. 
3.2.3 Synthesis of the protected spacer (N-2-(tert-butyloxycarbonyl) amino-
N,N-bis(3-(dimethylamino)propyl)-acetamide)  
Prior to the synthesis of phy-7NH-m (m = 12, 16, and 18), a starting reagent 
(chemical 8 in Scheme 3.3) having a NH group within the spacer needs a protection 
of –NH group by replacing the hydrogen of the amine group with a tert-
butoxycarbonyl (BOC) group. The BOC group is one of most frequently used for 
protection of NH2 or NH groups. There are several reagents used for the introduction 
of BOC group.199 Di-tert-butyl dicarbonate (Boc2O) is the best in most applications 
because of its high stability and low price. The N-protection of the amine can be 
carried out in acetonitrile using dimethylaminopyridine (DMAP) as base. The method 
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used in this study was that of Hara et al.200 In our experiment, 3,3’-iminobis(N,N-
dimethylpropylamine) (chemical 8 in Scheme 3.3, Sigma-Aldrich, USA) was added 
to Boc2O (Sigma-Aldrich, USA) in the presence of DMAP (Sigma-Aldrich, USA), at 
the molar ratio of 1:1:1.1, and stirred at room temperature for 2 h. The reaction was 
followed thin layer chromatography (TLC) with hexane (EMD chemicals, USA): ethyl 
acetate (Fisher Scientific, Canada) (50:50) as solvent until completion. The solvent 
was removed under reduced pressure. The crude product was purified by 
recrystallization (hexane:ethyl acetate, 50:50) to give a pure product. The purified 
product, named N-2-(tert-butyloxycarbonyl) amino-N,N-bis(3-(dimethylamino)propyl)-
acetamide, was characterized by 1H NMR. The NMR data is given in Appendix A. 
3.2.4 Synthesis of phy-7NH-m (m = 12, 16, and 18) 
The same method as for the synthesis of phy-3-m was used to make phy-7NH-m. 
The BOC-protected 3,3’-iminobis(N,N-dimethylpropylamine) (1.08 g, 3.75 mmol, 
chemical 8 in Scheme 3.3) was added to phytanyl bromide (1.08 g, 3.00 mmol) in 30 
mL of anhydrous acetonitrile. The mixture was stirred at 50 °C for 3 days. The 
solvent was reduced by rotary evaporator to approximately 1 mL. The mixture was 
transferred to another round bottom flask to which 1-bromododecane (Acros 
Organics), 1-bromohexadecane (Acros Organics), or 1-bromooctadecane (Acros 
Organics) was added with 10 mL of acetonitrile and refluxed for 24 h. The molar 
ratio of product 9 in scheme 3.3 to 1-bromododecane or 1-bromohexadecane or 1-
bromooctadecane (Acros Organics) was 1:2.25 (Scheme 3.3). After 24 h, the 
mixture was cooled to room temperature and transferred to a 250 mL round bottom 
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flask. HCl (6N) was added to the mixture in the presence of 40 mL of 
dichloromethane. The molar ratio of BOC and HCl was 1:1. The mixture was 
refluxed for 2 h. The solvent was removed by rotary evaporation. The crude product 
was recrystallized and produced the final products phy-7NH-m (m=12, 16, and 18) 
(Scheme 3.3). The purified products were characterized by 1H NMR. The NMR data 
is given in Appendix A. 
 
Scheme 3.3 Synthesis of phy-7NH-m (m=12, 16, and 18). i. Boc2O, DMAP, CNCH3, 
2 h; ii. product 3 from scheme 3.1, CH3CN, 50°C, 3 days; iii. RBr, CNCH3, reflux, 24 
h; iv. HCl, CH2Cl2, reflux, 2 h. 
3.2.5 Characterization of the phytanyl substituted gemini surfactants 
The characterization of the phytanyl substituted gemini surfactants was carried out 
using Krafft temperature, surface tension, specific conductance, particle size, and 
transmission electron microscopy methods.   
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3.2.5.1 Krafft Temperature 
For ionic surfactants, the solubility undergoes a sharp increase at some 
temperature, commonly referred to as the Krafft temperature (TK).
146 In this study, TK 
was determined using the specific conductivity method as previously reported.201 To 
determine TK, clear and saturated aqueous solutions of phy-3-m compounds were 
prepared and placed in a refrigerator overnight, where the precipitation of the 
surfactants occurred. The precipitated system was introduced into a temperature-
controlled vessel. Temperature was controlled to  0.05 oC with a Lauda model 
RE304 (Lauda, Germany) circulating water bath. The initial temperature was set to ≤ 
10 oC and then was incrementally increased. The conductivity of the solution was 
measured as a function of temperature using the conductivity meter (Fisher 
Scientific). The cell constant of the conductivity meter is 0.475 cm-1. The Krafft 
temperature was taken the temperature where the curve of conductance vs. 
temperature shows a sharp break in slopes, as indicated by the arrows in the plot 
presented in Figure 3.1. This break coincides with the temperature of full clarification 
of the surfactant system.    
3.2.5.2 Surface tension 
Surface tension was measured using a Lauda model TE3 automated tensiometer 
(Lauda, Germany) by the du Nuoy ring method; all surface tension values () 
were corrected by the method of Harkins and Jordan. The surface tension was 
measured after each titration of concentrated surfactant to 50 mL of milli-Q water 
at 25 °C or at a temperature indicated in the text. 
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Figure 3.1 Conductance vs. temperature behavior of surfactant solutions: 16-8-16 
(●) and 12-16-12 (Δ). The Krafft temperatures (TK) were indicated by the arrows.
201  
3.2.5.3 Specific conductivity  
Specific conductivities were determined using a conductivity meter (Fisher Scientific) 
with a cell constant of 0.475 cm-1. Experimental temperatures were maintained at 
25°C, unless otherwise indicated, by means of a Lauda model RE304 (Lauda, 
Germany) circulating water bath. The specific conductivity was measured after each 
addition of an aqueous solution of concentrated surfactant to 15 mL of milli-Q water 
under stirring. The specific conductivity as a function of concentration was obtained 
for each surfactant. 
3.2.5.4 Particle sizes 
Particle size of each surfactant was measured at 25 °C and/or a temperature 
indicated in the text by using a Malvern Zetasizer Nano ZS instrument (Malvern 
instruments, UK). The particle size distribution in water was obtained from the 
  70 
light scattered by particles which was illuminated with a laser beam ( = 173). 
The measured sizes are reported using a % volume distribution. Each data point 
was automatically repeated multiple times, and the average is reported. 
3.2.5.5 Transmission Electron Microscopy (TEM) 
The morphology of the phy-3-m compounds was observed by TEM. A 20 μL 
aliquot of each sample was dropped on a 300 mesh carbon coated copper grid 
for 30 to 60 seconds.The excess sample was drained off with filter paper and the 
deposited particles were stained with 1% (w/v) phosphotungstic acid (pH adjusted 
to 7 with 0.1N NaOH) for 20 seconds, and blotted with filter paper. The dried 
sample was examined with a JEOL 2010F TEM at the Canadian Centre for 
Electron Microscopy at McMaster University (Ontario, Canada). Measurements of 
bilayer thickness were made using a basic graphic drawing program and 
calibrating the resolution bar on each image to a known number of pixel elements.  
Measurements were made on three separate images at a minimum of three 
independent sites on each image for both the phy-3-12 and 12-3-12 systems (n = 
9, average standard deviation = 0.2 nm). 
3.2.6 In vitro transfection  
The transfection complexes are composed of the plasmid, gemini surfactant, DOPE, 
in OPTI-MEM medium (GIBCO®, Fisher Scientific, Canada). The plasmid,  pVGtelRL, 
coding enhanced green fluorescent protein (EGFP) gene,202 a gift from Dr. Roderick 
Slavcev (School of Pharmacy, University of Waterloo), was used at amount of 0.4 
g/well (0.4 g DNA = 0.6 nmol/bp) for the transfection.  All phytanyl substituted 
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gemini surfactants,16-3-16, and 12-7NH-12, were prepared at a concentration of 1.5 
mM, filtered through a 0.2 m of a sterile filter (Catalogue number 09719A, Fisher 
Scientific, Canada), and used at 4 L/well (6 nmol/well) to obtain a surfactant to 
plasmid charge ratio of 10:1. DOPE vesicles were prepared according to the method 
of Wettig et al,193 at a concentration of 1 mM in PBS (pH9) and filtered using  a 0.45 
m filter (Catalogue number 09719D, Fisher Scientific, Canada), and used at 15 
L/well for the transfection. The transfection complexes were prepared as follows. 
0.4g of pVGtelRL was mixed with 4 L of gemini surfactants solutions and 
incubated at room temperature for 15min; 15 L of DOPE vesicles were added to 
the mixture and incubated at room temperature for 30 min.  
Transfection assays were carried out as reported in a previous study.193 Briefly, 
one day prior to the transfection, OVCAR-3 cells were seeded in 24-well plate at a 
density of 1 x 105 cells/mL. The cells were incubated at 37 °C with 5% CO2 for 
approximately 24 h to reach 75% confluence on the day of the transfection. On the 
second day, the following steps were carried out, once the cell confluence reached 
approximately 75%. One hour prior to transfection, cells were washed with fresh 
phosphate buffered saline (PBS), and the old RPMI-1640 medium was replaced by 
the fresh RPMI-1640 medium without fetal bovine serum (FBS) and antibiotics. Then 
the transfection complexes were prepared as mentioned above and added to the 
cells dropwise. The cells were incubated at 37 °C with 5% CO2 for 5 h. Cells were 
also transfected using 16-3-16 and 12-7NH-12, LipofectamineTM 2000 (Invitrogen, 
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used according to the manufacturer’s protocol), plasmid only, and plasmid 
complexed with DOPE as controls. After 5 h incubation, the supernatant medium 
was replaced by fresh RPMI-1640 with 20% FBS and the cells were incubated at 
37 °C with 5% CO2 overnight for EGFP expression. On the third day, cells were 
collected and washed using PBS, and resuspended in PBS. The samples were 
analyzed with fluorescence activated cell sorting (FACS) instrument (BD 
FACSVantage SE). 10,000 cells were analyzed for each sample. The data was 
analyzed using WinMDI 2.9 software. Data are expressed as Mean ± SD (standard 
deviation), and statistical analysis was performed by One-Way ANOVA with a 
Tukey’s post hoc test using Origin software. 
3.3 Results and Discussion 
3.3.1 Krafft temperature (Tk) 
For phy-3-12, no precipitation of the surfactant occurred after overnight incubation in 
the refrigerator. It had to be frozen and then be melted slowly at room temperature to 
obtain a precipitation. Under the experimental measuring conditions, the phy-3-12 
solution did not show any precipitate. For this system, Tk was considered below 
room temperature. Different from the phy-3-12, precipitates occurred for phy-3-16 
and phy-3-18 systems. The conductance of these two surfactant systems was 
measured with the increased temperature. The Tk values for phy-3-16 and phy-3-18 
were obtained from the plots presented in Figure 3.2. The Krafft temperature is  
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Figure 3.2 Determination of the Krafft temperature of the phy-3-m (m = 16 and 18). 
The Krafft temperature was taken as the temperature where the plot showed a 
break. The arrows indicate the Tk and TP of the surfactant systems. The plotted data 
are seen in Table B-1 in Appendix B. The plotted data is referred to Wang and 
Wettig.203 
indicated in the plots of phy-3-16 and phy-3-18 by arrows and listed in Table 3.1. As 
we observed, Tk values of phy-3-m (m = 12, 16, and 18) increased with the 
increased alkyl tail length. This trend is in agreement with the observation in the m-
3-m (m=12, 16, and 18) listed in Table 3.1. Zana and Xia summarized general trends 
of TK values for ionic surfactants. One is that TK increases with the alkyl tail carbon 
atoms,146 our results from phy-3-m fits this general trend. This is ascribed to the 
increased hydrophobicity of a surfactant system with a longer alkyl tail length, which 
can allow increase of Krafft temperatures. Increase of TK with the hydrophobicity of 
alkyl tails can also be observed from the comparison of phy-3-m with m-3-m (m =12, 
16, and 18). The bulky nature of phytanyl tail in the phy-3-m compounds results in a 
higher Tk values compared to the m-3-m surfactants. 
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Compared to the conductance vs. temperature behavior of phy-3-m (m = 16 and 
18), phy-3-16 showed a gradual rise below the Krafft temperature, while a steep rise 
in conductance was observed for phy-3-18. This may be caused by a greater 
solubility for the phy-3-16 at temperatures below the Krafft temperature compared to 
phy-3-18. Additionally, the curve for phy-3-18 showed a high similarity to 12-16-12 
surfactant, which is reported to form vesicles above TK.
201 
Table 3.1 The Krafft temperature (TK) and Krafft point (TP) of the gemini surfactants  
Gemini surfactant TK (°C) TP (°C) 
Phy-3-12 < room temperature < room temperature 
Phy-3-16 67.4 45 
Phy-3-18 79.5 64.2 
12-3-12 12.7201 - 
16-3-16 42.0204 - 
18-3-18 45.3204 - 
Note: TP was misunderstood as TK in a published article: Wang H., Wettig SD., PCCP, 2011. 
 
It is important to note that Krafft temperature is different from Krafft point (TP), 
which is defined as the temperature where the solubility of surfactant monomers 
becomes equal to the CMC.205 Above the TP, micelles begin to form, which produces 
a rapid increase in the solubility of the surfactant. Thus, conductance of the 
surfactant system increases sharply with increased temperature beginning at TP until 
TK is reached.
206 Thus, the Krafft temperature of an ionic surfactant is usually higher 
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than its Krafft point. The Krafft point is as important as the Krafft temperature for a 
surfactant system since TP describes the temperature at which micelle starts to form 
and TK indicates the temperature of full clarification of a surfactant system. Thus, 
researchers can decide experimental temperature depending on a study objective. 
Based on the conductivity measurements, the TP values of phy-3-m were obtained 
and are given in Table 3.1.To obtain CMC values of phy-3-m using surface tension 
or specific conductivity, experimental temperature was selected based on their Tp 
values.  
3.3.2 Surface tension and head group area 
The surface tension as a function of the logarithm of surfactant concentration for the 
phy-3-m (m = 12, 16, and 18) at different temperature is plotted in Figure 3.3. Critical 
micelle concentration (CMC) can be determined by the measurement of surface 
tension. In a plot of surface tension as a function of the logarithm of surfactant 
concentration, the CMC is found as the point where two lines intersect: the baseline 
of minimal surface tension and the slope where surface tension shows a linear 
decline. Operationally, CMC is determined from regression analysis of the region 
where surface tension linearly decreased and the post-micellar region. The CMC 
values of phy-3-m (m = 12, 16, and 18) are listed in Table 3.2. The CMC for the phy-
3-12 at 25 °C is 0.07 mM, much lower than the value for the 12-3-12 (0.98 mM). The 
value of CMC for the phy-3-16 at 50 °C is 0.0057 mM, which is around 5 times lower 
than that of the 16-3-16. The same trend was observed for the phy-3-18.  
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Figure 3.3 Surface tension vs. Log concentration for the phy-3-12 at 25 °C , phy-
3-16 at 50 °C,and phy-3-18 at 65 °C. The lines are linear fits. Values of CMC, 
indicated by arrows, are determined from the intersection of two lines. The plotted 
data is seen in Table B-2 in Appendix B. The plot is referred to Wang and 
Wettig.203 
A plot of the logarithm of the CMC as a function of hydrocarbon tail length for the 
phytanyl compounds is seen in Figure 3.4. As expected, approximately linear line 
with some minor variation for long tail lengths (m = 18) is observed, which is also 
reported in other studies.207 This observation is attributed to premicellar aggregate 
  77 
formation.207 The Klevens constant, B, defined as the slopes of the log cmc vs. m 
plots, for the majority of gemini surfactants are 0.43 ± 0.03,146 which is larger than 
the values of 0.27 – 0.3 for conventional quaternary ammonium surfactants.149 The 
larger value of B reflects the increased hydrophobicity of the gemini surfactants, 
where the length of both tail groups are usually varied to maintain the overall 
symmetry of the molecule. When one varies the length of only a single tail group in 
the gemini surfactant (i.e. m-6-6 and phy-3-m), the Klevens constants (0.23 for m-6-
6208 and 0.27 for phy-3-m) are again observed to fall below 0.3 similar to that 
observed for traditional quaternary ammonium surfactants. 
The head group area (a0) for the phytanyl compounds are calculated from the 
surface excess concentration according to the following equation: 
                         
                                         (Equation  3.1) 
where NA is Avogadro's number, 6.022 x 10
23, and is the surface excess 
concentration obtained from the Gibb’s adsorption equation:  
  
                         
 
        
 
  
     
                           (Equation 3.2) 
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Figure 3.4 Variation of the logarithm cmc as a function of alkyl tail length for the 
gemini surfactants: m-3-m (, data from reference44 ) phy-3-m (,); m-6-6 (, data 
from reference208 ). The plot is referred to Wang and Wettig.203 
In Equation 3.2 R and T have their usual meaning, n is a constant accounting for 
the dissociation of ionic surfactants, and for the gemini surfactants n=3.163 The 
head group area for the phytanyl substituted gemini surfactants are listed in 
Table 3.2. The head group area decreased with the decreased alkyl length of 
phy-3-m (m = 12, 16, and 18). In another word, the head group area decreased 
with increased dissymmetry (C16:C12 > C16:C16 > C16:C18), indicating that the 
packing of surfactant molecules with a higher dissymmetry is more dense at the 
air-water interface. This trend is also observed in 16-2-8 (C16:C8) and 14-2-12 
(C14:C12) surfactants, which have a head group area of 0.68 nm
2/molecule and 
0.81 nm2/molecule, respectively.209 For these types of asymmetric gemini 
surfactants with short spacer groups (s = 2 or 3), the dominant factor in 
determining the variation in head group area is the interaction between the 
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hydrophobic tails since they do have the same length of spacer groups. W ith the 
increased dissymmetry, the attractive interaction between two tails becomes 
stronger, which results in a reduction of head group area. 
However, a different trend was observed from the comparison of phy-3-m with 
their symmetric surfactants (m-3-m).The head group areas for the phy-3-12 and 
phy-3-16 surfactants are noticably smaller than those for the 12-3-12 and 16-3-16 
surfactants (1.11 nm2/molecule and 1.21 nm2/molecule, respectively44) while that 
for phy-3-18 is approximately 1.5 times that reported for 18-3-18 (1.28 
nm2/molecule210). Such a discrepancy has also been reported by others. For 
example, 12-2-12 had a head group area of 1.02 nm2/molecule209, higher than 
those for 16-2-8 and 14-2-12; the head group area of 12-6-12 (1.40 
nm2/molecule44, 156) is bigger than that of 12-6-14 (1.28 nm2/molecule211); while 
compared to 12-10-12 (2.20 nm2/molecule156), 12-10-14 (2.48 nm2/molecule211) 
exhibited a higher head group area.  
Table 3.2 Critical micelle concentration (CMC) and head group area (a0) obtained by 
surface tension measurements.  
Surfactant CMC (mM) a0 (nm
2 molecule-1) 
Phy-3-12 0.07 ± 0.0001 0.78 ± 0.09 
Phy-3-16 0.0057 ± 0.0005 0.91 ± 0.05 
Phy-3-18 0.0054 ± 0.0004 1.92 ±0.06 
12-3-1244 0.98 ± 0.04 1.11 
16-3-1644 0.026 ± 0.001 1.21 
18-3-18210           0.013 ± 0.001 1.28 
Note: the table is referred to Wang and Wettig.203  
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3.3.3 Conductivity measurement 
The graphs of specific conductivity versus concentration of the phytanyl 
compounds are plotted in Figure 3.5. Critical micelle concentration is usually 
estimated from the abrupt change of specific conductivity vs. concentration curve.  
However, a frequent problem arises when the conductivity-concentration plot 
exhibits a weak curvature. In this case, it is very difficult to determine the break in 
the conductivity-concentration plots and then the CMC values are affected by a 
great uncertainty. To solve this problem, an alternative procedure was proposed 
and has been used to obtain CMC and other application, for example, a study on 
the effect of ethylene glycol addition on the micellization of 
tetradecyltrimethylammonium bromide.212 In this method, the CMC values were 
determined from a fit of the conductivity-concentration plots ( vs. c) according to 
the method of Carpena et al.213, using the relation (Equation 3.4):  

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1
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         (Equation 3.3) 
where 0 represents the conductivity at c = 0, A1 and A2 are the asymptotic 
values  for small and large values of c, respectively, and dx is a constant, which 
accounts for the width of the CMC transition region.  
The CMC values obtained from the specific conductivity measurements are listed 
in Table 3.3. The CMC of phy-3-12 obtained from specific conductance was 0.063 
mM, which is very consistent with the value obtained from surface tension  
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Figure 3.5 Specific conductivity vs. concentration for phy-3-12 at 25 °C, phy-3-16 at 
50 °C, and phy-3-18 at 65 °C. The lines are the best fits of data to the equation 3.4. 
The experimental data is listed in Table B-3 in Appendix B. The data is referred to 
Wang and Wettig.203 
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measurements (Table 3.2). Poorer agreement is obtained for the phy-3-16 and phy-
3-18 surfactants, which may be as a result of the different properties measured by 
these techniques and potentially due to the accuracy of the different methods.149 
Regardless, the same trend of decreasing CMC with increasing m is observed with 
both methods.  
In addition, based on Equation 3.3, the degree of micelle ionization () can be 
obtained from the ratio of A2/A1. This parameter,  is defined as a fraction of an 
ionic surfactant’s counterions that are dissociated from micelles, leaving the micelles 
charged.214  Generally, counterion binding increases with increasing alkyl tail length 
for an ionic surfactant,215, 216  which means  decreases with the increased tail 
length for ionic surfactants. The trend of decrease of  on increasing alkyl tail length 
has been ascribed to the increased micelle surface charge density on increasing tail 
length.216   For example, For CmH2m+1(CH3)3N
+Br-,  values decreased from 0.35 to 
0.16 in going from m = 8 to 16 216( data presented in Figure 3.6). As the results 
shown in this study,  values of phy-3-m varied with the tail length. It seems 
inconsistent with the general trend mentioned above. This is caused by the different 
measuring temperature of  (phy-3-12 at 25 °C, phy-3-16 at 50 °C and phy-3-18 at 
65°C). An increase of  with temperature has been reported by others.216-218 The 
reaction that a bromide ion dissociates from a micelle is believed to be 
endothermic.216 Hence, increasing temperature facilitates the dissociation of 
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counterions from the micelles, resulting in an increased . This is also the reason 
why  values of 16-3-16 and 18-3-18 are higher than that of 12-3-13 (Table 3.3). 
  
Figure 3.6 Variations of degree of micelle ionization () with alkyl tail length of 
CmH2m+1(CH3)3N
+Br- at 25°C(data from reference216).  
The charge of a micelle is very important in such applications that employing the 
micelle as a charged interface, such as for transgene delivery. The higher , the 
easier the counterions can be replaced by other anionic ions. For example, the 
higher degree of ionization for the phy-3-16 indicates that the counter ions (Br-) 
would be more readily replaced when mixed with DNA, as compared to 16-3-16. 
Compared to the symmetric corresponding ones, the phy-3-m showed a higher 
Table 3.3), which is an advantage of the phy-3-m applied to gene therapy as non-
viral vectors. 
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Table 3.3 Critical micelle concentration (CMC) and degree of micelle ionization () 
obtained from conductivity measurements. 
Surfactant CMC (mM)  
Phy-3-12 0.063 ± 0.003 0.46 ± 0.01 
Phy-3-16a 0.031 ± 0.001 0.67 ± 0.02 
Phy-3-18b 0.027 ± 0.002 0.44 ± 0.03 
12-3-1244 0.98 ± 0.04 0.23 ± 0.02 
16-3-16219 0.026 ± 0.001 0.35 ± 0.02 
18-3-18204 0.028 ± 0.002 0.32 ± 0.05 
ameasured at 50°C, bmeasured at 65°C. The table is referred to Wang and Wetitg.203 
3.3.4 Aggregate shape and particle size of the phytanyl substituted surfactants 
Due to the increased hydrophobicity and bulky nature of the phytanyl group relative 
to a hexadecyl tail, phytanyl substitution dramatically impacts the molecular packing. 
The shape of aggregates formed by the phytanyl compounds was predicted from 
calculation of the packing parameter. As introduced in the section 1.3.1, the packing 
parameter (P) can be calculated based on the volume and length of the hydrocarbon 
tail, and the head group area. The volume of the hydrocarbon tail can be estimated 
from known values for the volume of methylene and methyl groups according to: 
                                                                (Equation 3.4) 
Where Vmethylene  27 Å
3 and Vmethyl  54 Å
3; n and m are the number of carbons in 
the methylene and methyl groups, respectively220. The length of hydrocarbon tails 
can be calculated from the following equation149: 
                                                                               (Equation 3.5) 
Where nc is the number of carbons in the alkyl tail.  
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  The calculated values of the volume, length, and the packing parameter for the 
phy-3-m and their corresponding ones are reported in Table 3.4 where the total 
volume of the hydrophobic tails is given by (v1 + v2) and the length of the 
hydrophobic group will be equal to the length of the longest tail. As seen in Table 
3.4, as well as in the literature (both from prior calculations of P and experimental 
measurements), aggregates formed by m-3-m gemini surfactants tend to form 
cylindrical micelles with a P value of approximately 0.35 depending upon the alkyl 
tail length. The replacement of one of the tail groups by a phytanyl chain significantly 
increases the hydrophobic volume (due to the bulkiness of the additional methyl 
group branches) without impacting the overall length of the hydrophobic group 
(except for the phy-3-12 surfactant).  This restricts the geometry of the system such 
that vesicles are now the predicted favorable geometry, as seen experimentally by 
the larger particle diameters, 13 nm for phy-3-12, 46 nm for phy-3-16, and 30 nm for 
phy-3-18, that are consistent with vesicle formation (Table 3.4). 
Table 3.4 Calculated packing parameter (P) and measured particle sizes (diameter, 
d) for the phy-3-m and m-3-m (m=12, 16, and 18). 
Surfactant a0 (Å
2)a v1 (Å
3)b v2 (Å
3)b l (Å)c P d (nm) 
Phy-3-12 78 595 351 21.74 0.59 13  5 
Phy-3-16 91 595 459 21.74 0.53 46  1 
Phy-3-18 192 595 513 24.27 0.24 30  4 
12-3-12 111d 351 351 16.68 0.38 2.20.2e 
16-3-16 121d 459 459 21.74 0.35 3.30.2 e 
18-3-18 128f 513 513 24.27 0.33 4.40.05 e 
Note: a from Table 3.2; b from equation 3.5; c from equation 3.6; d from reference ;208 e from 
reference;204 f from reference.210 The table is referred to Wang and Wetitg.203 
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  To investigate the nature of micellar aggregates, the phy-3-m was imaged by 
TEM and the images of the phy-3-12 and 12-3-12 were illustrated in Figure 3.7. The 
TEM images support the finding that the phy-3-m compounds prefer to form a 
stacked bilayer-type of aggregate rather than spherical or the rod-like micelles which 
are typically observed in gemini surfactants with shorter spacer groups.  
As can be seen in Figure 3.7, micelles observed for the 12-3-12 are smaller and 
less organized than those for the phy-3-12. Furthermore, analysis of the spacing 
between layers in Figure 3.7 for phy-3-12 gives an average spacing of 4.6 ± 0.2 nm 
(n=9), or approximately 2.3 nm as the thickness of a monolayer. This corresponds 
well with the calculated length of the phytanyl chain (2.174 nm or 21.74 Å from Table 
3.4). The corresponding thickness of rod-shaped structures observed for the 12-3-12 
micelles is around 3.2± 0.2 nm (n=10), giving a monolayer thickness of 1.6 nm, 
again in good agreement with the calculated length of a dodecyl chain (16.68 Å from 
Table 3.4). 
The exception to the above is the phy-3-18 surfactant, which has a head group 
area of 192 Å2 per molecule and results in a P value of 0.24 which would predict the 
formation of spherical micelles. It should be noted however, that the equilibrium 
surface tension method may not give truly representative values for the head group 
area, and suggests that these calculations may need to be repeated with molecular 
areas derived from Langmuir – Blodgett film studies. Nevertheless, given our interest 
in designing novel surfactants for gene therapy applications, the constraint on 
molecular geometries resulting from phytanyl substitution may ultimately prove 
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useful in the formation of lipoplexes with higher orders of bilayer structure, known to 
favorably increase transfection efficiencies.168 
 
 
 
Figure 3.7 Transmission electronic micrographs of phy-3-12 (upper) and 12-3-12 
(lower), bar represents 50 nm. Red arrows represent stacked bilayers in the upper 
graph, and rod-shaped micelles in the lower graph. Concentrations of 12-3-12 and 
phy-3-12 were 4.9 and 0.35 mM, respectively. The plot is referred to Wang and 
Wettig.203 
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3.3.5 Preliminary investigation on transfection activity of the phytanyl 
substituted gemini surfactants 
The capacity of phytanyl substituted compounds for gene delivery was investigated 
in OVCAR-3 cells, and EGFP expressed in the cells is shown in Figure 3.8. The phy-
3-m series of compounds exhibited significantly higher EGFP expression as 
compared to the 16-3-16 surfactant (p < 0.1), previously demonstrated to be efficient 
in not only in vitro transfection, but also as an in vivo topical treatment using a 
mouse model.152 Such promising results could be interpreted as following. The 
higher degree of micelle ionization of phy-3-m could produce the favorable formation 
of gemini surfactant-DNA complex. Additionally, the bulky nature of phytanyl 
substitution that results in vesicle formation without DNA could give rise to the 
formation of higher order structures upon complexation with DNA, which is similar to 
what is observed with DOPE and 12-3-12 surfactant as previously reported.188  
The other series of phytanyl compounds, phy-7NH-m, were not able to deliver 
EGFP in OVCAR-3 cells, shown in Figure 3.8. Additionally, 12-7NH-12 showed poor 
transfection ability in OVCAR-3 cells. The lack of transfection ability for the phy-7NH-
m and 12-7NH-12 is in disagreement with the expected results reported by Wettig et 
al..193 The amino-substituted 12-7NH-12 showed great Luciferase expression in 
COS7 cells, significantly higher than 12-3-12 did. Different cell lines have an 
effect(s) on transgene efficiency. Cell surface receptors and possible roles related to 
the cellular binding may depend on cell lines. For example, heparan sulfate 
proteoglycans (HSPGs), located in cellular membrane and functioning as specific 
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growth factors, has been reported to vary in cell lines,107 which then influences 
HSPGs mediated binding in gene transfection. In addition, transfection efficiency 
may not truly describe transfection ability of a delivery vector. It only gives how much 
proteins expressed in the cells, but no information about efficiency of the delivery 
vector internalized in the cells, escaped from endosomes, and DNA release from the 
complexes. Thus, the above limitations of using transfection efficiency to measure 
transfection ability of a delivery vector should be considered when evaluating 
transfection ability of the delivery vector. Meanwhile, other techniques, such as 
confocal, may be employed to track a delivery vector inside cells.   
 
Figure 3.8 In vitro transfection of OVCAR-3 cells with plasmid-gemini surfactant-
DOPE complexes. Data are also presented for cells without any treatment, treated 
by plasmid with and without DOPE, and Lipofectamine TM 2000. Significant 
differences between phy-3-m (m = 12, 16, and 18) and 16-3-16 were observed (p < 
0.1) (n = 3 except for complexes formed by phy-7NH-m, error bar = standard 
deviation). The plotting data are given in Appendix E. The data of phy-3-m and 16-3-
16 is referred to Wang and Wettig.203 
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3.4 Conclusions 
The phytanyl substituted gemini surfactants, phy-3-m and phy-7NH-m (m = 12, 16, 
and 18) were synthesized. The aggregation properties of phy-3-m were 
characterized. The Krafft temperature of phy-3-m increased with the tail length, 
consistent with general observations for other gemini surfactants. Compared to their 
symmetric m-3-m compounds, phy-3-m showed much lower CMC values due to the 
higher hydrophobicity caused by the phytanyl substitution. The higher degree of 
micelle ionization () of phy-3-m indicates that phy-3-m compounds more readily 
form DNA-surfactant complexes compared to their symmetric m-3-m. Head group 
areas for phy-3-m compounds are smaller than those for the m-3-m surfactants (with 
the exception of phy-3-18) and likely point to the increased affinity of the alkyl tail 
group of the phtanyl compounds for the more hydrophobic air side of the air-water 
interface. 
Packing parameters calculated for the phy-3-m compounds are indicative of the 
formation of vesicles, which is in agreement with experimental determination of 
particle diameters and the morphologies imaged by TEM. Such structures are 
advantageous in forcing the preferential formation of higher order bilayer structures 
(i.e. inverted hexagonal and/or cubic) upon complexing with DNA. Preliminary 
transfection assays in vitro demonstrated that the phytanyl substitution does result in 
increased transfection efficiencies, compared to the symmetric 16-3-16 surfactant. 
 
 
  91 
Chapter 4 Transfection and structural properties of phytanyl 
substituted gemini surfactant-based vectors for gene delivery 
4.1 Introduction 
As introduced in Chapter 1, application of cationic gemini surfactants as transgene 
delivery vectors for gene therapy has been attracting more and more researchers. 
To evaluate the ability of a non-viral vector to deliver transgenes, transfection assays 
are a must. Transfection efficiency depends on many factors, such as chemical 
structure of cationic surfactants, formulation of transfection complexes (i.e. ratio of 
cationic vector to DNA, corporation with or without a helper lipid), the type of cell 
line, duration of post-transfection (time for transgene expression), transfection 
complex surface charge, and structures of the complexes, etc. General observations 
based on studies about m-s-m type of gemini surfactants as transgene delivery 
vectors have been listed in Chapter 1.  
A group of phytanyl substituted asymmetric gemini surfactants, phy-3-m (m = 12, 
16, and 18) was rationally designed, synthesized, and characterized. One of the 
primary goals of our study is to develop suitable gemini surfactant-based vectors for 
ovarian cancer gene therapy. Thus, the ability of phy-3-m to transfect ovarian cancer 
cells is the first step. The preliminary results showed that phy-3-m can be able to 
deliver transgene in an ovarian cancer cell line, as described in the previous chapter. 
In this chapter, transfection ability of phy-3-m was investigated by varying the ratio of 
surfactant to DNA; transfection complexes were characterized by measuring particle 
size and zeta potential; and complex structures were studied with small angle X-ray 
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scattering. All of these measurements provide valuable information that can aid in 
the optimization of phytanyl gemini surfactants-based gene delivery system for 
ovarian cancer gene therapy; moreover, study on structural activity of phy-3-m will 
assist in the rational design of more surfactants that are efficient in transgene 
delivery.   
4.2 Methods and Materials 
Phy-3-m (m =12, 16, and 18) and 16-3-16 were synthesized as described in the 
previous chapter. The plasmid used in the study was pVGtelRL coding enhanced 
green fluorescent protein (EGFP) gene,202 a gift from Dr. Roderick Slavcev (School 
of Pharmacy, University of Waterloo). The amplification of the plasmid was done in 
our laboratory. DOPE was prepared at 1 mM in PBS (pH9) according to the method 
introduced in section 3.2.6. Lipofectamine TM 2000 was purchased from Invitrogen 
and used according to the manufacturer’s protocol. 
4.2.1 The preparation of the plasmid 
To obtain enough plasmid for in vitro transfection experiments, the plasmid 
pVGtelRL was prepared from E.coli grown in Luria Bertani (LB) medium with 0.1% 
(v/v) kanamycin. After overnight growth, the plasmids were extracted and purified 
using a PureYieldTM Plasmid Midiprep System kit (Promega, USA). Briefly, the 
culture was centrifuged at 5,000 x g for 10 min; cell pellets were resuspended; cell 
lysis solution was added and incubated for 3 min at room temperature; cell lysate 
was obtained after adding neutralization solution and centrifuging at 15,000 x g at 
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room temperature. DNA was purified from cell lysate using the Clearing Column and 
Binding Columns offered in the kit. The Binding Column was washed with the 
provided Endotoxin Removal and Column Wash solutions, and dried by applying a 
vacuum for 30-60 seconds. 600 L of Nuclease-free water was added to the DNA 
binding membrane and the Binding Column was centrifuged at 2,000 x g for 5 min 
using a swinging bucket rotor. The purified DNA was quantified by Nanodrop 2000 
spectrophototmeter (Thermo Scientific,Canada).  
4.2.2 OVCAR-3 Cell preparation  
Transfection study was performed using OVCAR-3. OVCAR-3 cells were grown on 
75 cm2 tissue culture flasks in 15-20 mL RPMI-1640 medium (HyClone®, Fisher 
Scientific, Canada) supplemented with 20% of fetal bovine serum (FBS) (Fisher 
Scientific, Canada) and 1% of Penicillin-Streptomycin (antibiotics) (Fisher Scientific, 
Canada). The cells were incubated at 37 °C with 5% CO2 in tissue culture incubator. 
4.2.3 Transfection assay 
All gemini surfactants were prepared at 1.5 mM, filtered through a 0.2 m of a sterile 
filter (Catalogue number 09719A, Fisher Scientific, Canada). The molar ratio of 
gemini surfactant to DOPE was kept at 1:2.5 since the complexes at this ratio are 
able to transfect cells efficiently as showed in the previous chapter. The transfection 
complexes were prepared as follows: 0.4g of pVGtelRL was mixed with aliquots of 
sterile gemini surfactant solutions to obtain a gemini surfactant/DNA charge ratio of 
2:1, 5:1, 10:1, or 20:1, and incubated at room temperature for 15 min. To this 
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mixture, an aliquot of DOPE vesicles were added to keep the molar ratio of 
surfactant to DOPE at 1:2.5, and incubated at room temperature for 30 min to allow 
the transfection complexes to form, followed by addition of the complexes to cells 
according to the transfection protocol mentioned in section 3.2.6. After 5 h 
incubation, the supernatant medium on the cells were replaced by the fresh RPMI-
1640 with 20% of FBS. The resulting EGFP expression was determined in 
approximately 18 h.  
4.2.4 Fluorescence microscopy  
Before harvesting the cells, Images of EGFP expressed in OVCAR-3 cells were 
obtained using a PTI (Photon Technology International, Canada) image system 
equipped with a Nikon fluorescence microscopy (Nikon Eclipse Ti, Japan). Samples 
were excited at a wavelength of 470 nm and emission was monitored at 510 nm.   
4.2.5 Fluorescence activated cell sorting (FACS) 
The EGFP expression and cell viability was quantified using FACS technique. 
Briefly, cells were detached using 0.25% trypsin-EDTA (Fisher Scientific, Canada), 
pooled for each treatment condition, then centrifuged at 4 °C and 1800 rpm for 7 
min. The cell pellet was washed with PBS twice and resuspended in 350 L of PBS. 
To determine the cytotoxicities of the treatments, 10 L of propidium iodide (PI, 50 
mg/mL) was added to each sample and incubated in an ice bath for at least 30 min 
before the FACS analysis. 10,000 cells for each sample were counted using a BD 
FACSVantage SE instrument (Biology, University of Waterloo). The data was 
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analyzed using WinMDI 2.9 software. Data are expressed as Mean ± SE (standard 
error).   
4.2.6 Characterization of the transfection complexes 
The transfection complexes were prepared as described earlier for the transfection 
assay, with the exception that, the complexes were prepared in milli-Q water instead 
of OPTI-MEM medium (GIBCO®, Fisher Scientific, Canada) in larger volumes (1 
mL). Fresh transfection complexes were prepared at charge ratios (+/-) of 2:1, 5:1, 
and 10:1. Initial characterization of the complexes was carried out by measuring 
particle size and zeta potential of the nanoparticles. The measurement of the particle 
size and zeta potential was carried out using a Malvern Zetasizer Nano ZS 
instrument (Malvern instrument, UK).  
The method to determine the particle size was described earlier. The 
measurement of zeta potential of the complexes was performed by using 
electrophoretic light scattering. Zeta potentials were measured using disposable 
Malvern zeta potential cells, illustrated in Figure 4.1. When an electric filed is applied 
across a sample, charged particles suspended in the sample attract toward the 
electrode of opposite charge. Their velocity is measured using Laser Doppler 
Velocimetry (LDV) technique. The zeta potential of the particle is obtained in terms 
of the Henry equation:221    
        
    , where UE is electrophoretic mobility,  
is dielectric constant,  is zeta potential,  is viscosity, and f () is Henry’s function. 
The velocity of a particle in an electric field is referred to its electrophoretic mobility. 
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Thus, calculation of zeta potential from the electrophoretic mobility is straightforward. 
Operationally, the laser beam passes through the center of the sample cell and 
scattering light at an angle of 17o is detected. The samples were prepared by the 
same method as the one used for measuring particle size. All measurements were 
made at 25 °C. Size measurements of transfection complexes are expressed as a % 
intensity basis.  All measurements were repeated multiple times and results are 
reported as the mean ± standard deviation.  
 
Figure 4.1 A classical cell for measuring zeta potential.221  
4.2.7 Small angle X-ray scattering (SAXS) 
The samples for SAXS were prepared as following. DOPE and a gemini surfactant 
were mixed in chloroform (Fisher Scientific, Canada). The solvent was evaporated 
under reduced pressure. The dry mixture was hydrated using milli-Q water to make 
lipid mixture. The final concentration of DOPE and the gemini surfactant in the lipid 
mixture was 100 mM and 40 mM, respectively, which gives the mole ratio of gemini 
surfactant to DOPE at 1:2.5. The salmon sperm DNA (Sigma) was prepared at 20 
mM in milli-Q water as a stock. A portion of 150 L of the DNA was added into 150, 
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375, and 750 L of the above lipid mixture to make complexes at the charge ratios of 
2:1, 5:1, and 10:1, respectively. The samples were then vortexed for 30 seconds, 
and placed at 4 °C prior to SAXS investigation. 
SAXS experiments were performed using a SAXSess mc2 instrument (Anton Paar, 
Austria), located in Dr. Eric Prouzet’s group in the Department of Chemistry at the 
University of Waterloo. The wavelength of X-ray generated is 0.154 nm. SAXSess 
mc2 has a sample-to-detector distance of 0.267 m. The scattering pattern is 
recorded by an imaging plate reader at a size of 15 x 5 cm (L x W) (Anton Paar, 
Austria), and 2D scattering pattern is integrated into a one-dimensional scattering 
plot using SAXSquantTM software (Anton Paar, Austria); the one-dimensional 
scattering plot is the scattering intensity as a function of q, where q is the scattering 
vector. The scattering wave vector (q) is given by222   
       
 
 , where 2  is the 
scattering angle and  is the wavelength of X-ray. In this study, the data was 
collected in a q-range from 0 to 3 nm-1. 
The sample was loaded into the capillary sample holder (Anton Paar, Austria) at 
room temperature and equilibrated for at least 10 min. The scattering was scanned 
for 30 min and the scattering pattern was recorded on the image plate. All spectra 
were subtracted from the background which is the scattering profile obtained for a 
capillary containing water only. The data acquisition and analysis was performed 
using the SAXSquantTM software (Anton Paar, Austria). The scattering peaks were 
fitted according to a Gaussian function using the fityk software.193 
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4.2.8 Statistical analysis 
Statistical analysis was performed by One-Way ANOVA with a Tukey’s post hoc test 
using Origin software. 
4.3 Results and Discussion 
The ratio of gemini surfactant to DNA influences many properties, such as surface 
charge of the complexes, particle size, the phase structure(s) the complexes form, 
all of which are known to impact transfection efficiency and cytotoxicity. To 
investigate the influence of the amount of gemini surfactants on DNA delivery, a 
series of transfection complexes formulated at different charge ratios of the gemini 
surfactants to DNA was tested in OVCAR-3 cells. The charge ratios of the gemini 
surfactant to DNA were 2:1, 5:1, 10:1, and 20:1. 
4.3.1 Evaluation of transfection efficiency in vitro   
4.3.1.1 EGFP expression imaged using fluorescence microscopy 
Firstly, the transfected OVCAR-3 cells were observed using fluorescence 
microscopy. Representative images are displayed in Figure 4.2. The black 
background without any bright spots indicates that the protein EGFP has not been 
expressed in the cells, while the cells expressing EGFP showed bright spots. The 
images (Figure 4.2 a, b, and g) obtained from non-treated OVCAR-3 cells, the cells 
transfected by plasmid only, and the cells treated with the complexes formed by the 
phy-3-16 compound at 20:1, did not show any bright spots, indicating there is no 
EGFP expressed in the cells. This is in agreement with the results obtained with 
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FACS analysis, shown in the next paragraph. Bright spots were found in the images 
(Figure 4.2 c, d, e, and f) obtained from the cells transfected by Lipofectamine TM 
2000, and the complexes formed by the phy-3-16 compound at the charge ratios of 
2:1, 5:1, and 10:1, indicating that Lipofectamine TM 2000, and the gemini surfactants 
at charge ratios of 2:1, 5:1, and 10:1, can deliver EGFP into the OVCAR-3 cells. 
Fluorescence microscopic images for transfection complexes formed by other 
gemini surfactants are seen in Appendix D.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 EGFP images for non-treated cells (a), cells treated with plasmid only (b), 
cells treated with LipofectamineTM 2000 (c), and cells treated with complexes 
comprised of phy3-16, plasmid, and DOPE at charge ratios of 2:1 (d), 5:1 (e), 10:1 
(f), and 20:1 (g). The bright spots represent live cells expressing EGFP. 
 
 
 
 
a                                         b                                        c                          
d                                    e                                     f                                     g 
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4.3.1.2 EGFP expression quantification using FACS 
To quantitatively evaluate EGFP expression in the OVCAR-3 cells and to measure 
cell toxicities, the transfected cells were analyzed using FACS. The dot plots 
obtained for the controls and treatments are shown in Figure 4.3. Live cells positive 
for EGFP are counted along the X-axis and are differentiated from the dying or dead 
cells positive for propidium iodide (PI) counted along the Y-axis. The upper right 
quadrant of the plots indicates the dying or dead cells expressing EGFP. According 
to our results, no EGFP-positive cells were found in the samples of non-treated cells 
(Figure 4.3a), or for cells treated with the plasmid only (Figure 4.3b). Live cells 
expressing EGFP were observed for the positive control (treatment with 
Lipofectamine TM 2000, Figure 4.3c) and in cells treated with the gemini surfactants 
at charge ratios of 2:1, 5:1,10:1, and 20:1 (Taking phy-3-16 as an example, seen in 
Figure 4.3 d to g). PI-positive cells along the Y-axis were found in all samples, 
indicating that some techniques involved in the transfection assays are toxic to cells. 
These techniques include the detachment reagent (trypsin) and detaching time, and 
resuspension medium (PBS) for FACS measurement.  
EGFP-positive cells were quantified and plotted in Figure 4.4A. As a positive 
control, the commercial vector Lipofectamine TM 2000 showed 32.2% of EGFP 
expression in OVCAR-3 cells while untreated cells did not show any EGFP 
expression. No EGFP expression was found for cells treated by plasmid with and 
without DOPE, but without gemini surfactant. For complexes containing the phytanyl  
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Figure 4.3 FACS dot plots for OVCAR-3 cells: untreated (a), cells treated with 
plasmid only (b), Lipofectamine TM 2000 (c), and phy-3-16 at charge ratios of 2:1 (d), 
5:1 (e), 10:1 (f), and 20:1 (g). The points in the plot correspond to the cells. The cells 
positive for EGFP distribute along the X-axis, the cells positive for PI distribute along 
the Y-axis, and the upper right quadrant of the plot indicates cells positive for both 
EGFP and PI.   
substituted gemini surfactants at charge ratios between 2:1 to 10:1, significant 
EGFP-positive cells were observed compared to non-treated cells (p < 0.001), 
indicating that the plasmid coding EGFP was successfully delivered by the gemini 
surfactant based system. At 2:1, phy-3-16 compound achieved 16.4% of EGFP, 
significantly higher than those obtained with phy-3-12 and phy-3-18 (p < 0.2); while 
both phy-3-12 and phy-3-18 showed a high level of EGFP expression though the 
difference between them was not significant. At 10:1, EGFP expression slightly 
dropped for all gemini surfactants compared to transfection efficiencies observed at 
5:1, but not significantly changed. At 20:1, less than 1% of EGFP expression was 
a                                      b                                         c                          
d                                      e                                      f                                        g 
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observed for the complexes containing the phytanyl compounds, a dramatic 
decrease of transfection efficiency probably caused by increased cytotoxicity at 
higher charge ratios (+/-). Due to poor transfection efficiency at 20:1, further 
experiments did not contain this treatment. As expected, the positive control 16-3-16 
also demonstrated the ability to deliver genes in OVCAR-3 cells, but at substantially 
lower levels. For example, at 5:1, approximately 15.5% of EGFP was observed from 
both phy-3-16 and phy-3-18, significantly higher that from 16-3-16 (p < 0.1).  
  To improve tranfection ability of gemini surfactant-based non-viral vectors, 
variations in alkyl tail length or the nature and length of spacer group have been 
investigated.  Recent studies have shown that transfection efficiency increases with 
the alkyl tail length.194, 223 Three groups of surfactants: m-3-m, m-7-m, and m-7NH-m 
(m = 12, 16, and 18), were reported to be able to deliver Luciferase gene in PAM 
212 cells.194 The transfection efficiency of Luciferase expression increased with the 
alky tail length, as an order of m = 12 < m = 16 < m = 18, although the difference 
between any two of them was not statistically significant in most cases. This is in 
agreement with our results that phy-3-12 showed the lowest level of EGFP 
expression in OVCAR-3 cells compared to the other two compounds. The increased 
tail length of surfactants results in increased hydrophobicity, which can enhance 
compaction with DNA molecules. The resulting transfection efficiency, however, is 
not enhanced as strongly as the enhancement observed from the variations in 
spacer group of gemini surfactants.  For example, IFN expression in PAM 212 cells 
decreased with the increased spacer length of 12-s-12 (s = 4, 6, 8, 10, 12, and 16), 
  103 
the lowest observed from 12-8-12, then increased with the spacer length.187 
Compared to m-7-m group, m-3-m (m = 12, 16, and 18) showed higher Luciferase 
expression in PAM 212 cells, though the difference between these two groups are 
not statistically significant.194  
Although the enhancement correlated with variations in tail length of phy-3-m was 
not statistically significant, the improvement of transfection efficiency due to the 
introduction of phytanyl group was significant in most cases. It was found that the 
phytanyl substituted compounds showed higher transfection efficiency than the 
positive control, 16-3-16. The enhancement is significant for most cases (i.e. at 
charge ratios of 10:1 and 5:1). This is consistent with the results obtained from the 
previous chapter.   
Another observation based on this study is that no clear trend for transfection 
efficiency was observed with varied charge ratios, though the charge ratio of the 
gemini surfactant to DNA is clearly observed to influence the transfection efficiency. 
The effect of charge ratio on EGFP expression is illustrated in Figure 4.4B. For each 
gemini surfactant complex, the transfection efficiency goes through a more or less 
well-evidenced maximum, occurring at different values of the charge ratio. The 
maximum value of transfection is observed at a charge ratio of 5:1 for the complexes 
containing phy-3-12 and phy-3-18, and also observed at 2:1 for the complexes 
formed by phy-3-16.  Charge ratio effect on transfection efficiency has been reported  
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Figure 4.4 EGFP expression in OVCAR-3 cells was quantified by FACS. (A) The 
cells were transfected by the complexes composed of the gemini surfactant, 
pVGtelRL, and DOPE at charge ratio of 2:1, 5:1, 10:1, and 20:1, respectively. The 
cells were treated by the plasmid with and without DOPE, and also treated by 
Lipofectamine TM 2000 as a positive control; cells growing in the medium without any 
treatment were taken as a negative control. The data (except 20:1) is the mean of 
EGFP expression in the cells (n = 5, error bar = standard error). (B) Comparison of 
transfection efficiency at charge ratios of 2:1, 5:1, and 10:1. Data are the same as 
those for plotting graph A. * represents that at p < 0.2, EGFP expression observed 
from phy-3-16 is significantly higher than those obtained with phy-3-12 and phy-3-
18, at the ratio of  2:1; # indicates that at p < 0.1, transfection efficiencies obtained 
both from phy-3-16 and phy-3-18 are significantly higher than that from 16-3-16 at 
charge ratio of 5:1; & describes that a significant difference was observed between 
phy-3-m and 16-3-16 at p < 0.1. 
by other investigators. Badea et al. showed that GFP expression in PAM 212 cells 
varied with the charge ratio (+/-) of 16-3-16 to pGTmCMV.IFN-GFP plasmid, the 
highest GFP expression observed at 40:1, then at 10:1, 5:1, and lowest at 20:1.187 
Donkuru found that the highest Luciferase expression in PAM 212 was achieved at 
charge ratio (+/-) of 10:1 for m-3-m, m-7-m, and m-7NH-m (m = 12, 16, and 18) 
surfactants to pMASIA. Luc plasmid.194 Such a discrepancy could be resulted from 
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cell line type and plasmid size used in these studies. Additionally, it should be noted 
that plasmid conformation (e.g. supercoiled vs. linear) may affect the effective 
charge ratio (+/-). Due to a compact form, some negatively charged phosphate 
groups may be wrapped in the supercoiled plasmid, which reduces the number of 
free negative charges (phosphate groups) on the surface of the plasmid.  
4.3.1.3 Cytotoxicity of transfection complexes 
Our final goal is to find better gemini surfactant-based gene delivery system. Thus, 
cytotoxicity is one of major concerns to evaluate the feasibility of gemini surfactant 
as gene delivery vectors. Cytotoxicity of transfection complexes as a function of 
surfactant/DNA charge ratio for all the system in this study is shown in Figure 4.5. 
For each sample, the DNA amount was maintained constant and the gemini 
surfactant amount was varied in order to obtain the desired charge ratios. As 
assessed by FACS, the results were expressed as the percentage of viable cells. As 
observed, the higher surfactant/DNA charge ratio, the higher was the observed 
toxicity. As a general trend, for all transfection complexes, a more or less significant 
increase of cytotoxicity as a function of the charge ratio increase is evidenced. The 
increased toxicity can be attributed to the free gemini surfactants whose quaternary 
ammonium head groups and counterions have been reported to be toxic.224 In 
addition, phy-3-m showed lower toxic effect on the cells than 16-3-16 did. This may 
be related to the different interactions of the surfactants with cell membrane.  
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Figure 4.5 Cell viability for OVCAR-3 cells (expressed as percentage of viable cells) 
varied with charge ratios for the transfection complexes containing phy-3-12 (■), 
phy-3-16 (Δ), phy-3-18 (▲), or 16-3-16 (○). At all charge ratios, cell viability is 
significantly higher for the complexes containing phy-3-m than that for the 16-3-16 
delivery complex (p < 0.05). Data are also presented for non-treated cells and cells 
treated with Lipofectamine TM 2000 (indicated by ●). All data is the mean of viable 
cells (n = 5, error bar = standard error).   
Although it has been found that cationic surfactants with higher CMC are more 
toxic to bacteria, the toxicity towards mammalian cells varies differently; for example, 
the toxicity of the surfactants to E.coli was shown as an order: C10TAB > C12TAB > 
C14TAB, while to an epithelium cell model, the order was: C12TAB > C10TAB > 
C14TAB.
224 Such a difference may be attributed to the different physico-chemical 
properties of cell membranes and the interactions of surfactants with cells. 
Given cellular cytotoxicity, it is desirable for cancer gene therapy since cancer 
cells are killed by a delivery vector due to its toxicity. As long as delivery vectors are 
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targeted to cancer cells, their cellular toxicity may not be a consideration for their 
application to cancer gene therapy. But for other gene therapies, cellular cytotoxicity 
is still a major factor. 
4.3.2 Characterization of transfection complexes (size and zeta potential)  
Transfection complexes were characterized by measuring their particle size and zeta 
potential. The importance of particle size for gene transfection has been reported. 
Although the optimal lipoplex size for efficient gene delivery is still under debate,225, 
226 there is a general agreement that lipoplex size plays a significant role in 
determining the nature of the entry pathway of the lipoplexes into the cells.127, 227-229 
On one hand, the larger complexes result in more cell membrane contact and active 
phagocytosis. On the other hand, particles with larger versus smaller size may enter 
cells through different internalization mechanisms. As introduced in chapter 1, 
endocytosis has been widely accepted as the major pathway of lipoplex 
internalization into the cells.119 Two distinct endocytic pathways: clathrin-mediated 
and caveolin-mediated endocytosis, have been investigated (see in Figure 4.6). A 
size-dependent mechanism has been proposed.127 With the clathrin-mediated 
pathway inhibited, B16F10 (murine melanoma cell line) cells showed a significant 
inhibition of internalization of nanoparticles with sizes between 200 and 50 nm, while 
the uptake of those with a size of 500 nm was unaltered or even slightly higher, 
which means large particles are internalized through a different pathway. Moreover, 
the uptake of the 500 nm particles was reduced by more than 50% due to the 
blockage of caveolin-mediated pathway. Further experiments revealed that the 
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internalization of the 500 nm particles occurred through caveolin-mediated pathway. 
It has been hypothesized that larger particles are even more efficient in transgene 
delivery because they are internalized through caveolin-mediated pathway, therefore 
avoiding lysosomal targeting as occurs along the clathrin-mediated mechanism.230   
 
 
Figure 4.6 Two main endocytotic pathways for lipoplexes: clathrin-mediated and 
caveolin-mediated endocytosis.119 
The size and zeta potential of the transfection complexes was measured and 
tabulated in Table 4.1. Without compaction, the plasmid was 360 nm. With varied 
charge ratios, the particle size dramatically changed, indicating the effect of charge 
ratio on DNA confirmation. DNA structure change induced by the gemini surfactant 
has been investigated using circular dichroism (CD) measurement. It has been 
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reported that the dramatic change of signal intensity and band shift of CD spectrum 
caused by the increase in the charge ratio indicates the conformational change in 
DNA molecules upon binding with the gemini surfactant.175, 231 
Table 4.1 Size and zeta potential measurements of the transfection complexes at 
different charge ratios of gemini surfactants to DNA. 
 Size (nm) a -potential (mV)a 
DOPE 
114 ± 12 -32 ± 5 
Plasmid 
360 ± 90 -65 ± 3 
DOPE+ 
Plasmid 
172 ± 5 -10 ± 4 
Surfactant 2:1 5:1 10:1 2:1 5:1 10:1 
Phy-3-12 1220 ± 73 343 ± 77 188 ± 9 13 ± 1 31 ± 4 37 ± 5 
Phy-3-16 1619 ± 125 899 ± 27 169 ± 8 12 ± 1 27 ± 4 44 ± 8 
Phy-3-18 1361 ± 124 404 ± 64 151 ± 10 12 ± 1 38 ± 3 41 ± 7 
16-3-16 709 ± 95 460 ± 40 130 ± 6 14 ± 1 28 ± 2 32 ± 7 
a Mean ± standard deviation. DOPE and DNA inclusive in all surfactants.  
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The transfection complexes at the lower charge ratios of 2:1 and 5:1 were 
observed to be large. It has been reported that particle size for 14-2-14:Chol:DOPE 
lipoplexes was 1634 nm at charge ratio (+/-) of 2:1, but dropped to 173 nm at 8:1.232 
This is consistent with our results. At the lower charge ratios, the plasmid may not be 
completely compacted by the gemini surfactant, which results in the formation of 
larger particles. At the charge ratio of 10:1, all complexes had sizes less than 200 
nm, indicating the plasmid was more completely compacted by the gemini 
surfactants. At higher charge ratios, transfection complexes with smaller size have 
been reported. For example, at charge ratio (+/-) of 10:1, particle size for complexes 
composed of 12-s-12, plasmid, and DOPE, were below 200 nm and approximately 
200 nm for the complexes containing 16-3-16.188  
As can be seen from particle size and transfection data (Figure 4.4), for the phy-3-
16, the results displayed a marked increase of the transfection with the complex size 
increase. This is also observed from other m-s-m surfactants. For example, 16-3-16 
showed higher transfection ability than 12-3-12.187, 188 Larger particles giving rise to 
higher transfection efficiency has been evidenced.120, 225 This may be attributed to 
their efficiency in delivering transgenes through phagocytosis or caveolin-mediated 
cellular pathway. However, for the phy-3-12 and phy-3-18, there is no clear trend 
observed with the increase in the complex size. Thus, no specific correlation can be 
concluded between particle size and transfection efficiency. Transfection complexes 
with larger size may enter cells through a different pathway compared to those 
smaller particles.   
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The surface charge represented by the zeta potential has been reported as a 
factor for lipoplex stability and interaction with cell membrane.119, 233 For the 
complexes containing phy-3-m (m = 12, 16, and 18), the zeta potential were above 
+30 mV at the charge ratio greater than 5:1, indicating that the complexes are 
normally stable. Compared with transfection results, no correlation was observed 
between the zeta potential and transfection efficiency. This is in agreement with the 
observation from 12-s-12 (s = 2, 3, 4, 6, 8, 10, 12, and16) and 16-3-16 
compounds.188 Nevertheless, transfection complexes with positive charges are 
needed not only for effective transfection but also for complexes stability.   
4.3.3 Structures investigation using SAXS 
One of the applications of the SAXS technique is to provide structural information on 
polymorphic systems, such as highly ordered lipoplexes composed of cationic lipid 
and DNA, or partially ordered membranes or lipid mesophases. Lipoplexes resulting 
in a self-assembled complex with ordered structures were extensively investigated 
by synchrotron SAXS and shown to influence transfection efficiencies.94, 96, 103, 136, 234, 
235 Using SAXS diffraction method, an ordered mesophase appears as one or more 
sharp peaks, named Bragg peaks, in the diffraction pattern. The long-range ordering 
of the lipid/water aggregates (i.e. bilayers, cylinders, micelles) onto 1-, 2-, or 3-
demensional lattices produces Bragg peaks whose reciprocal spacings (shkl = 1/dhkl) 
are characteristic of special ratios.236 For lamellar lipid-water mesophases: sl = 
 
  ,
236 d is the lamellar repeat distance, which is the thickness of the lipid bilayer (m) 
plus that of the adjacent water layer (w) (seen in Figure 1.3). The ratio of distances 
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between neighbouring bilayers follows a pattern of 1:2:3:...; the Bragg peaks occur 
at the scattering vector q =     . For hexagonally arranged mesophases: shk = 2 
(h2+k2+hk)1/2/√3a,236 where a is the distance between the centers of two 
neighbouring rods (seen in Figure 1.3). The hexagonal phases are characteristic of 
the peaks at the ratios of 1:√3:2:…; the Bragg peaks occur at   
  
   
         .93  For cubic phase: shkl = (h
2+k2+l2)1/2/a,236 it is characteristic of 
1:√2:√3:...; the Bragg peaks occur at   
  
 
         .93 The letters, h, k, and l in 
the above equations are Miller indices, a notation system in crystallography for 
planes in crystal lattices, and the detailed description is referred to Hopcroft et al..237 
In this study, the internal structure of the complexes composed of gemini 
surfactant, plasmid, and DOPE, at different charge ratios (+/-) was investigated 
using SAXS. The mixture of DOPE and gemini surfactant was made at a molar ratio 
of 1:2.5 (surfactant to lipid) and maintained constant for all complexes at the different 
charge ratios of gemini surfactant to DNA. The SAXS profile for the mixture of the 
gemini surfactant and DOPE consists of a single broad peak and no long-range 
ordering was observed (Figure 4.7A). This feature has been reported to be 
characteristic of interparticle interactions between the nanoparticles.152 The addition 
of plasmid DNA to the mixture of the surfactant and neutral lipid resulted in 
significant changes in the scattering profiles (see Figure 4.7B-E). Interlayer spacing 
for lamellar phases and unit cell spacing for hexagonal phases are calculated and 
tabulated in Table 4.2.  
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Figure 4.7 SAXS profiles of the lipid mixture of DOPE and 16-3-16 (A), and the 
complexes formed phy-3-12 (B), phy-3-16 (C), phy-3-18 (D), or 16-3-16 (E), plasmid, 
and DOPE, at the charge ratios of 2:1, 5:1, and 10:1. Black solid arrows represent 
the lamellar phase peaks. Dotted arrows indicate the peaks identified as the inverted 
hexagonal or cubic phases. All spectra were subtracting from the blank (water as a 
blank). 
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The most notable change is the appearance of narrow peaks instead of a single 
broad peak. For the complexes containing phy-3-12 at different charge ratios, two 
scattering peaks, one sharp and the other weak, were present in the profiles. These 
two scattering peaks are characteristic of a lamellar phase which is identified by the 
peaks position in the ratio of 1:2. The peaks of the periodic lamellar structures 
display an interlayer distance approximately 6.4 nm which is independent of the 
charge ratio of phy-3-12 to DNA. The spacing between layers for pure phy-3-12 is 
4.6 ± 0.2 nm, the result obtained from TEM imaging given in Figure 3.7. The 
diameter for DNA is around 2.0 nm, thus, the distance of a lamellar structure 
containing phy-3-12 bilayers with intercalated monolayers of DNA is approximately 
6.6 nm (4.6+2.0), which matches very well the distances calculated from the 
scattering vector q.  
For complexes containing phy-3-16, different SAXS profiles were observed at 
different charge ratios. At 2:1, two scattering peaks appeared at 0.946 nm-1 and 
1.905 nm-1, identifying as a lamellar structure (L) with an interlayer spacing of 6.64 
nm (       = 6.64 nm). It was observed that peak splitting occurred at 1.072 nm
-1 
and 1.857 nm-1, respectively, characteristic of an inverted hexagonal phase structure 
with a unit cell spacing of a     
     
  =  6.77 nm. Additionally, two peaks 
corresponding to another phase were observed at 0.753 nm-1 and 1.521 nm-1, 
respectively. In addition, there are a few weak peaks that do not correspond to a 
lamellar or hexagonal phase. Due to the finite information extracted from SAXS 
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spectra, it is difficult to assign these peaks. However, they are indicative of the 
presence of an unidentified phase(s).  
Table 4.2 Structural parameters and possible phase structures of the complexes 
composed of gemini surfactant, plasmid, and DOPE, at different charge ratios. 
Surfactant Charge 
ratio 
(+/-) 
q (nm-1) d (nm) a (nm) Phase 
 
Phy-3-12 
2:1 
0.975,1.953 
0.919 
6.45 
 
 
L 
Others 
5:1 
0.982,1.982 
0.946 
6.39 
 
 
L 
Others 
10:1 
0.966,1.974 
1.368,0.759 
6.50 
 
 
L 
Others 
 
 
 
 
Phy-3-16 
2:1 
0.946,1.905 
0.753,1.521 
1.072,1.857 
0.317,0.856,1.038,1.18,1.255 
6.64 
 
 
 
 
 
6.77 
 
L 
 
HII 
Others 
5:1 
0.908,1.563 
0.161,0.313,0.856,2.616 
 
 
7.99 
 
HII 
Others 
10:1 
0.91,1.554 
0.182,0.359,0.785,1.223,1.7 
 
7.97 
 
HII 
Others 
 
Phy-3-18 
2:1 
0.884,1.79 
0.987 
7.10 
 
 
L 
 
5:1 
0.755,1.304 
0.773,0.946 
 
9.62 HII 
Other 
10:1 
0.973, 1.927 
0.828, 1.17, 1.694 
0.626,0.738 
6.52 
 
 
 
 
L 
Q 
Others 
 
16-3-16 
2:1 
0.945, 1.895 
1.932 
6.65 
 
 
L 
 
5:1 0.954,1.928 6.59  L 
10:1 0.932,1.511,0.846   Others 
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By contrast, the scattering peaks for complexes formed by phy-3-16 at 5:1 and 
10:1 are less in quantity. At both ratios, the first and second-order peaks 
corresponding to an inverted hexagonal phase occur at q = 0.91 nm
-1 and q = 1.55 
nm-1. The inverted hexagonal phase at both ratios has a unit cell spacing of 
approximately 8 nm, indicating that the distance between two neighbouring rods 
from the inverted hexagonal lattice may reach to a maximum in the complexes at 
5:1. With the increase in the charge ratio, the spacing of one unit cell kept constant. 
Additionally, SAXS profiles show two peaks at q < 0.5 nm-1. However, it is difficult to 
assign these peaks due to the finite information.   
Figure 4.8D shows SAXS profiles for the complexes containing phy-3-18 at 
different charge ratios. At 2:1, the position of the main peak corresponds to a 
lamellar phase, consistent with the observation presented for the complexes 
containing 12-s-12 (s = 3, 8, and 16).179 The interlayer spacing for the lamellar phase 
is 7.10 nm, which is larger than those observed from the complexes formed by phy-
3-16 or phy-3-12 at 2:1. This may be caused by the larger bilayer spacing of pure 
phy-3-18 due to its longer C18 tail. At 5:1, a sharp peak appeared at q = 0.946 nm
-1, 
and peak splitting occurred at q10 = 0.755 and q11 = 1.304 nm
-1 respectively, 
corresponding to an inverted hexagonal phase with a unit cell spacing of 9.62 nm. At 
10:1, coexistence of lamellar and cubic phase structures is observed. The peaks of a 
lamellar phase occur at q = 0.973 nm
-1 and 1.927 nm-1. Peak splitting is an evidence 
that was observed at q = 0.828 nm
-1, 1.17 nm-1, and 1.694 nm-1, corresponding to a 
cubic phase.    
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As a positive control, the SAXS profiles for complexes containing 16-3-16 display 
a lamellar phase structure at both ratios of 2:1 and 5:1, and weakly scattering peaks 
which do not correspond to a lamellar or inverted hexagonal phase at 10:1. 
Compared to the phy-3-m system described above, it is evidenced that the 16-3-16 
system clearly lacks complexity on polymorphic characteristics. This noticeable 
difference is attributed to the use of the phy-3-m compounds. As expected, the 
introduction of phytanyl branch into gemini surfactants as one of tails increases the 
number of polymorphic phases formed with plasmid and DOPE.    
SAXS study is particularly important since it can provide information to predict the 
correlation of morphologies of transfection complexes with transfection efficiency. 
Tenchov et al. demonstrate that highly efficient cationic lipids promote the formation 
of an inverted cubic phase.238 This correlation may be ascribed to enhanced 
fusogenicity of the lipoplexes. Zuhorn et al. indicate that the formation of inverted 
hexagonal structure is crucial for efficient cellular internaliztion and endosomal 
escape of transgene.132 Lamellar lipoplexes may achieve higher transfection 
efficiency because they remain stable when in contact with membranes.96 
Polymorphic structures have been reported to be an important factor for efficient 
transfection.188  Wettig et al. found the presence of multiple phase formed by the 
amino-substituted gemini surfactant 12-7NH-12, which was highly efficient.193 In this 
study, SAXS results indicate that the complexes formed by plasmid, DOPE, and 
phy-3-m, are also able to adopt multiple phases, such as lamellar, inverted 
  118 
hexagonal, cubic, and other indentified structures. This may be considered a reason 
why phy-3-m compounds are efficient in gene delivery in OVCAR-3 cells.  
4.4 Conclusions 
Transfection ability of the phytanyl substituted gemini surfactants with a shorter 
spacer, phy-3-m (m = 12, 16, and 18), at different charge ratios (+/-) of surfactant to 
DNA, was investigated in OVCAR-3 cells. At charge ratios of 2:1, 5:1, and 10:1, 
EGFP expression can be observed in OVCAR-3 cells using fluorescence 
microscopy and FACS. Charge ratio of surfactant to DNA showed an effect on 
EGFP expression; transfection efficiency displayed highest values for phy-3-12 and 
phy-3-18 at 5:1, and also for phy-3-16 at 2:1. As a general observation, cytotoxicity 
increased with increased charge ratios. Thus, considering both transfection 
efficiency and cell viability, the optimal charge ratio for phy-3-m as transgene 
delivery vectors in OVCAR-3 cells is 5:1. This result will be helpful in the application 
of phy-3-m to the primary cells or in vivo study for ovarian cancer gene therapy.  
The characterization of the transfection complexes was carried out by measuring 
particle size and zeta potential. At lower charge ratios, transfection complexes 
showed larger particles. This is the evidence that size below 200 nm is not a 
requirement for higher transfection efficiency. Larger particles were efficient in 
transgene delivery, which may be ascribed to their different endocytosis mechanism. 
Although no correlation was observed between the surface charge and transfection 
efficiency, transfection complexes with positive zeta potential is needed not only for 
effective cellular interaction but also for enhanced stability.   
  119 
The complexes structure was investigated using SAXS. The phy-3-m system 
showed very notable polymorphic properties, while the 16-3-16 system lacked 
complexity on polymorphism. The ability of phy-3-m to adopt multiple phases may 
play an important role in enhancing transfection efficiency. In fact, combined with 
transfection results, it may provide evidence that transfection efficiency increased by 
increasing the number of polymorphic phases. At this point, our goal to improve 
transfection efficiency by introducing phytanyl group is achieved.    
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Chapter 5 Conclusions and future perspectives 
To improve transfection efficiency for gene therapy, one of the strategies is to design 
efficient vectors for transgene delivery. In this study, a series of phytanyl substituted 
gemini surfactants were rationally designed, synthesized, and characterized. Their 
transfection ability was evaluated in an ovarian cancer cell line to determine its 
application in vivo. It is the first time that the m-s-n type of asymmetric gemini 
surfactants having a bulky alkyl tail is synthesized and characterized; and 
transfection ability and phase structure investigation of the asymmetric gemini 
surfactants based gene delivery complexes is being reported firstly. 
Chapter 3 focuses on the synthesis and characterization of the phytanyl 
compounds, phy-3-m and phy-7NH-m (m = 12, 16, and 18). The results show that 
phy-3-m compounds have different aggregate properties, such as much lower CMC 
values, higher degree of micelle ionization, and the preference to form vesicle-like 
aggregates, compared to their symmetric ones (m-3-m). This project could be 
expanded using TEM or atomic force microscopy (AFM) imaging on phy-3-16, phy-
3-18, and their symmetric ones, to obtain all information about aggregate 
morphology of phy-3-m. As novel asymmetric gemini surfactants, it is interesting to 
know how many monomers aggregate to form vesicle-like micelles that were 
observed from phy-3-m. This study could be expanded by estimating aggregation 
number of phytanyl compounds using fluorescence quenching technique. The other 
group of phytanyl compounds, phy-7NH-m, was synthesized and they did not 
transfect OVCAR-3 cells effectively. However, no further studies on characterization 
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with phy-7NH- m were done in this project. From the perspective of a chemist, the 
future studies on phy-7NH- m characterization could be carried out to help 
understand why this group of compounds was not as efficient as phy-3-m.   
In this project, the comparison regarding surfactant aggregate properties was done 
between phy-3-m and m-3-m compounds. It would be interesting to look into the 
difference of phy-3-m with other asymmetric gemini surfactants (i.e. m’-3-n’) with 
three methylene units in the spacer, such as 12-3-16, 14-3-16, and 18-3-16, having 
the same alkyl tail length as phy-3-m. Further comparison with the m’-3-n’ could help 
us not only understand the effect of branched phytanyl group on the aggregate 
properties of the gemini surfactants, but also provide valuable information on rational 
design of gemini surfactants for practical applications. This is underway in our lab. 
The interaction between the gemini surfactants and DNA is another interesting 
study. Since the gemini surfactants were designed for gene delivery, it would be 
questioned that how the properties of gemini surfactants are influenced by the 
addition of DNA, or how the cationic gemini surfactants bind to anionic DNA 
molecules. This project could be expanded by the determination of critical aggregate 
concentration (CAC) using surface tensiometer, and thermodynamic investigation of 
the binding of the phytanyl compounds to DNA. Due to a strong intercalation of the 
pyrene group between DNA base pairs, the binding interaction between asymmetric 
pyrenyl-gemini surfactants and DNA has been reported to be distinctly different from 
the interaction observed from 12-s-12 and DNA.175 An intercalated binding for the 
phy-3-m compounds would not be found since there is no similarity between 
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phytanyl chain and pyrene structure. However, the branched phytanyl gemini 
surfactants would show different binding interactions compared to the 12-s-12 or 
other symmetric gemini surfactants. Such studies would help us understand the 
influence of gemini surfactant structures on the interaction with DNA and/or a 
possible mechanism(s) of DNA release from the gemini surfactant-DNA complexes 
during gene transfection. Moreover, it would provide valuable information for rational 
design of more efficient gemini surfactants in the future. 
The tranfection ability of the phytanyl compounds was examined in OVCAR-3 
cells, as reported in Chapter 4. The results indicate that phy-3-m is able to deliver 
plasmid DNA to OVCAR-3 cells, and showed higher transfection efficiency than 16-
3-16. Considering both transfection efficiency and cytotoxicity, the optimal charge 
ratio of surfactant to DNA for effective transfection was found to be 5:1. Initial 
characterization of the transfection complexes indicates that particles are larger at 
lower charge ratios and smaller than 200 nm at 10:1. These results provide evidence 
that small particles (i.e. less than 200 nm) are not a requirement for efficient 
transfection in vitro. This finding is consistent with results reported recently.188 
However, it would cause a problem for in vivo study because larger particles may be 
rapidly degraded by phagocytic cells and the reticuloendothelial system. Further 
studies using animal models should explore both charge ratios (+/-) of 5:1 and 10:1 
to investigate their resulting influence on gene delivery.  
Additionally, stability of transfection complexes may be increased by modifying 
transfection complexes with the attachment of polyethylene glycol (PEG) to the 
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nanoparticles. It would be interesting since no studies involving PEGylation of gemini 
surfactants-based DNA delivery vectors have been carried out. PEG conjugation 
approach, the length and conformation of PEG chain, the linkage to gemini 
surfactants-based nanoparticles, will be considered if the modification of transfection 
complexes with PEG is studied.  
The hypothesis of this project was that the asymmetric phytanyl chained gemini 
surfactants will improve transgene delivery efficiency because introducing phytanyl 
chain to the gemini surfactants may force the formation of transfection complexes 
with higher level morphologies. SAXS profiles displayed multiple phases observed 
from the complexes containing phy-3-m, while 16-3-16 system lacks the complexity 
of polymorphic properties. Thus, the structural investigation is the evidence that the 
phy-3-m compounds are able to form the flexible phase structures. Compared to the 
transfection results, the higher transfection efficiency achieved with phy-3-m system 
relative to 16-3-16 system appears correlated with their ability to adopt higher level 
bilayer structures.  
As evidenced, phy-3-m compounds showed high transfection efficiency in an 
established ovarian cancer cell line, OVCAR-3. Our primary goal is the development 
of efficient gemini surfactants as transgene delivery vectors for cancer gene therapy. 
Therefore, primary cells and/or animal models will be employed to investigate 
transgene delivery efficiency of phytanyl compounds in vivo studies. In cancer 
therapy, cell-specific targeting is one of considerations. Gemini surfactants can be 
flexibly attached with a targeting group (i.e. folate) that allow both increased cell 
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uptake and cell specificity. Transfection formulations formed by modified gemini 
surfactants with the conjugation of a target ligand and the resulting transfection 
ability should be investigated both at in vitro and in vivo levels.  
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Appendices 
Appendix A1H-NMR data for the synthesized compound  
Compound δ (ppm) Number of 
protons 
Group 
Phytanyl Bromide 0.80-0.94 
0.94-1.69 
3.34-3.49 
15 
24 
2 
CH3’s 
CH2’s and CH’s 
CH2Br 
Boc-protected 
3,3’-iminobis(N,N-
dimethylpropylamine) 
1.43 
1.86 
2.19 
6.45-6.47 
8.19-8.21 
4 
4 
4 
12 
9 
N(CH3)2-CH2CH2CH2 
N(CH3)2-CH2CH2CH2 
N(CH3)2-CH2CH2CH2 
N(CH3)2 
C (CH3)3 
Phy-3-12 0.81-0.85 
0.94-1.33 
1.46-1.77 
1.92 
2.74 
3.45-3.48 
3.87 
18 
38 
4 
2 
2 
16 
4 
CH3 (Phytanyl and C12 chains) 
CH2 (Phytanyl and C12 chains) 
CH (Phytanyl chain) 
CH2 (Phytanyl chain) 
CH2 (spacer) 
N-CH3, N-CH2 (chains) 
N-CH2 (spacer) 
Phy-3-16 0.81-0.85 
0.94-1.33 
1.46-1.77 
1.92 
18 
46 
4 
2 
CH3 (Phytanyl and C16 chains) 
CH2 (Phytanyl and C16 chains) 
CH (Phytanyl chain) 
CH2 (Phytanyl chain) 
  139 
2.74 
3.45-3.48 
3.87 
2 
16 
4 
CH2 (spacer) 
N-CH3, N-CH2 (chains) 
N-CH2 (spacer) 
Phy-3-18 0.81-0.85 
0.94-1.33 
1.46-1.77 
1.92 
2.74 
3.45-3.48 
3.87 
18 
50 
4 
2 
2 
16 
4 
CH3 (Phytanyl and C18 chains) 
CH2 (Phytanyl and C18 chains) 
CH (Phytanyl chain) 
CH2 (Phytanyl chain) 
CH2 (spacer) 
N-CH3, N-CH2 (chains) 
N-CH2 (spacer) 
Phy-7NH-12 0.80-0.87 
0.94-1.29 
1.40-1.55 
1.84 
2.62-2.70 
2.95 
3.24 
4.02-4.06 
18 
38 
4 
2 
4 
1 
16 
8 
CH3 (Phytanyl and C12 chains) 
CH2 (Phytanyl and C12 chains) 
CH (Phytanyl chain) 
CH2 (Phytanyl chain) 
NH-CH2 (spacer) 
NH (spacer) 
N-CH3, N-CH2 (chains) 
(CH3)2N-CH2- CH2 (spacer) 
Phy-7NH-16 0.80-0.87 
0.94-1.29 
1.40-1.55 
1.84 
18 
46 
4 
2 
CH3 (Phytanyl and C16 chains) 
CH2 (Phytanyl and C16 chains) 
CH (Phytanyl chain) 
CH2 (Phytanyl chain) 
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2.62-2.70 
2.95 
3.24 
4.02-4.06 
4 
1 
16 
8 
NH-CH2 (spacer) 
NH (spacer) 
N-CH3, N-CH2 (chains) 
(CH3)2N-CH2- CH2 (spacer) 
Phy-7NH-18 0.80-0.87 
0.94-1.29 
1.40-1.55 
1.84 
2.62-2.70 
2.95 
3.24 
4.02-4.06 
18 
50 
4 
2 
4 
1 
16 
8 
CH3 (Phytanyl and C18 chains) 
CH2 (Phytanyl and C18 chains) 
CH (Phytanyl chain) 
CH2 (Phytanyl chain) 
NH-CH2 (spacer) 
NH (spacer) 
N-CH3, N-CH2 (chains) 
(CH3)2N-CH2- CH2 (spacer) 
 
Appendix B Low resolution electrospray ionization mass spectroscopic data for the 
phytanyl substituted compounds 
Surfactant Gemini surfactant ion Results of analysis 
m/z %BPI 
Phy-3-12 
N
+
N
+
CH3 CH3
CH3
CH3
H25C12
C20H41
 
 
131.16 
150.19 
290.36 
299.38 
300.38 
411.51 
412.52 
3.73 
7.30 
30.41 
100.00 
23.33 
22.43 
7.48 
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Phy-3-16 
N
+
N
+
CH3 CH3
CH3
CH3
H33C16
C20H41
 
182.99 
290.33 
318.36 
346.40 
355.42 
411.48 
4.81 
3.61 
100.00 
10.84 
6.63 
3.01 
Phy-3-18 
N
+
N
+
CH3 CH3
CH3
CH3
H37C18
C20H41
 
149.02 
257.25 
318.37 
332.39 
346.40 
522.61 
550.64 
3.61 
6.02 
6.63 
100.00 
16.27 
7.23 
33.73 
 
Appendix C Characterization of the gemini surfactants 
 Table C 1 Specific conductivity vs. temperature 
Phy-3-16 
Temperature 
(°C) 
Conductivity (S/cm) Average ±SD Conductance 
(S) 
10 16.73 16.71 16.83 16.76 ± 0.06 35.28 
15 16.76 16.71 16.92 16.80 ± 0.11 35.36 
20 17.04 17.12 17.04 17.07 ± 0.05 35.93 
25 17.34 17.1 17.26 17.23 ± 0.12 36.28 
30 17.34 17.47 17.36 17.39 ± 0.07 36.61 
35 17.57 17.5 17.4 17.49 ± 0.08 36.82 
40 17.4 17.5 17.45 17.45 ± 0.05 36.74 
45 17.57 17.46 17.44 17.49 ± 0.07 36.82 
50 19.65 19.43 19.7 19.60 ± 0.14 41.25 
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55 22.13 22.28 22.45 22.29 ± 0.16 46.92 
60 24.02 24.57 24.41 24.33 ± 0.28 51.23 
65 26.67 26.78 26.69 26.71 ± 0.06 56.24 
70 27.71 27.89 28.1 27.90 ± 0.19 58.74 
75 28.51 28.41 28.43 28.45 ± 0.05 59.90 
80 29.16 29.40 29.21 29.26 ± 0.13 61.59 
85 30.60 30.70 30.30 30.53 ± 0.21 64.28 
90 31.30 31.40 30.50 31.07 ± 0.49 65.41 
 
Phy-3-18 
Temperature 
(°C) 
Conductivity (S/cm) Average ±SD Conductance 
(S) 
10 20.86 20.53 21.29 20.90 ± 0.38 43.99 
15 21.10 20.68 20.90 20.90 ± 0.21 43.99 
20 22.24 22.19 22.16 22.20 ± 0.04 46.73 
25 22.80 22.72 22.62 22.71 ± 0.09 47.82 
30 23.82 23.36 22.99 23.39 ± 0.42 49.24 
35 23.78 23.45 23.33 23.52 ± 0.23 49.52 
40 24.31 23.53 23.52 23.78 ± 0.45 50.08 
45 25.57 24.22 23.78 24.52 ± 0.93 51.63 
50 26.44 24.1 24.14 24.89 ± 1.33 52.41 
55 24.2 24.23 24.14 24.19 ± 0.04 50.93 
60 24.28 24.42 24.38 24.36 ± 0.07 51.28 
65 24.48 25.01 25.09 24.86 ± 0.33 52.34 
70 28.22 28.31 28.35 28.29 ± 0.06 59.56 
75 34.70 34.40 34.40 34.5 ± 0.17 72.63 
78 37.20 37.30 37.30 37.27 ± 0.06 78.46 
80 38.60 38.90 38.80 38.77 ± 0.15 81.61 
83 40.00 40.30 40.20 40.17 ± 0.15 84.56 
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85 41.10 41.30 41.30 41.23 ± 0.12 86.81 
88 42.60 42.90 42.90 42.80 ± 0.17 90.11 
 
Table C 2 Surface tension () vs. surfactant concentration 
Phy-3-12 
Concentration Log C  St.dev. Dosing Total Temperature 
( M) 
 
(mN/m) (mN/m) ml dos. ml °C 
0.00E+00 
 
67.05 0.039 0 0 25 
1.87E-07 -6.73E+00 67.12 0.2 0.005 0.005 25 
2.24E-07 -6.65E+00 67.41 0.016 0.001 0.006 25 
2.98E-07 -6.53E+00 67.39 0.005 0.002 0.008 25 
3.73E-07 -6.43E+00 67.3 0.14 0.002 0.01 25 
4.85E-07 -6.31E+00 67.36 0.018 0.003 0.013 25 
5.97E-07 -6.22E+00 67.3 0.021 0.003 0.016 25 
7.46E-07 -6.13E+00 67.22 0.027 0.004 0.02 25 
9.32E-07 -6.03E+00 67.05 0.0068 0.005 0.025 25 
1.19E-06 -5.92E+00 66.99 0.023 0.007 0.032 25 
1.49E-06 -5.83E+00 66.84 0.021 0.008 0.04 25 
1.90E-06 -5.72E+00 66.67 0.031 0.011 0.051 25 
2.39E-06 -5.62E+00 66.5 0.021 0.013 0.064 25 
2.98E-06 -5.53E+00 64.24 0.13 0.016 0.08 25 
3.76E-06 -5.42E+00 62.79 0.055 0.021 0.101 25 
4.73E-06 -5.33E+00 61.63 0.026 0.026 0.127 25 
5.95E-06 -5.23E+00 59.54 0.41 0.033 0.16 25 
7.51E-06 -5.12E+00 55.74 0.12 0.042 0.202 25 
9.47E-06 -5.02E+00 53.15 0.067 0.053 0.255 25 
1.19E-05 -4.92E+00 50.46 0.12 0.066 0.321 25 
1.50E-05 -4.82E+00 48.02 0.038 0.084 0.405 25 
1.89E-05 -4.72E+00 46.63 0.53 0.106 0.511 25 
2.38E-05 -4.62E+00 43.81 0.051 0.134 0.645 25 
2.99E-05 -4.52E+00 42.46 0.35 0.17 0.815 25 
3.77E-05 -4.42E+00 39.56 0.084 0.216 1.031 25 
4.75E-05 -4.32E+00 37.53 0.051 0.274 1.305 25 
5.98E-05 -4.22E+00 35.47 0.084 0.35 1.655 25 
7.53E-05 -4.12E+00 35.07 0.81 0.447 2.102 25 
9.48E-05 -4.02E+00 34.79 1.00 0.574 2.676 25 
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1.19E-04 -3.92E+00 34.03 0.41 0.741 3.417 25 
1.50E-04 -3.82E+00 33.81 0.41 0.963 4.38 25 
1.89E-04 -3.72E+00 33.23 0.064 1.263 5.643 25 
2.38E-04 -3.62E+00 33.75 1.20 1.677 7.32 25 
3.00E-04 -3.52E+00 32.55 2.00 2.261 9.581 25 
 
Phy-3-16 
Concentration log C  St.dev. Dosing Total Temperature 
M 
 
(mN/m) (mN/m) ml dos. ml °C 
0.00E+00 
 
67.39 0.13 0 0 50 
5.44E-08 -7.26E+00 66.67 0.07 0.006 0.006 50 
6.35E-08 -7.20E+00 66.31 0.024 0.001 0.007 50 
9.07E-08 -7.04E+00 66.18 0.017 0.003 0.01 50 
1.09E-07 -6.96E+00 66.15 0.016 0.002 0.012 50 
1.45E-07 -6.84E+00 66.01 0.052 0.004 0.016 50 
1.91E-07 -6.72E+00 66.01 0.059 0.005 0.021 50 
2.45E-07 -6.61E+00 66.06 0.0095 0.006 0.027 50 
3.17E-07 -6.50E+00 66.01 0.03 0.008 0.035 50 
4.08E-07 -6.39E+00 66.03 0.027 0.01 0.045 50 
5.26E-07 -6.28E+00 66.09 0.01 0.013 0.058 50 
6.79E-07 -6.17E+00 65.95 0.0027 0.017 0.075 50 
8.87E-07 -6.05E+00 64.65 0.13 0.023 0.098 50 
1.14E-06 -5.94E+00 61.61 0.28 0.028 0.126 50 
1.47E-06 -5.83E+00 57.56 0.34 0.037 0.163 50 
1.91E-06 -5.72E+00 52.03 0.38 0.048 0.211 50 
2.47E-06 -5.61E+00 47.66 0.28 0.063 0.274 50 
3.20E-06 -5.50E+00 43.9 0.32 0.081 0.355 50 
4.13E-06 -5.38E+00 40.91 0.29 0.105 0.46 50 
5.34E-06 -5.27E+00 37.74 0.21 0.136 0.596 50 
6.92E-06 -5.16E+00 37.33 0.46 0.178 0.774 50 
8.94E-06 -5.05E+00 36.03 0.12 0.231 1.005 50 
1.16E-05 -4.94E+00 36.16 0.26 0.303 1.308 50 
1.50E-05 -4.83E+00 34.18 0.075 0.397 1.705 50 
1.93E-05 -4.71E+00 38.09 1.5 0.522 2.227 50 
2.50E-05 -4.60E+00 34.26 0.14 0.692 2.919 50 
3.24E-05 -4.49E+00 37.62 0.81 0.922 3.841 50 
4.18E-05 -4.38E+00 35.65 2.10 1.241 5.082 50 
5.41E-05 -4.27E+00 36.97 1.50 1.693 6.775 50 
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7.00E-05 -4.15E+00 36.45 1.70 2.35 9.13 50 
 
Phy-3-18 
Concentration Log C  St.dev. Dosing Total Temperature 
M 
 
(mN/m) (mN/m) ml dos. ml °C 
0.00E+00 
 
67.63 0.3 0 0 65 
4.29E-08 -7.37E+00 65.21 0.16 0.006 0.006 65 
5.00E-08 -7.30E+00 64.26 0.087 0.001 0.007 65 
7.15E-08 -7.15E+00 63.48 0.15 0.003 0.01 65 
9.29E-08 -7.03E+00 63.16 0.092 0.003 0.013 65 
1.14E-07 -6.94E+00 63.33 0.027 0.003 0.016 65 
3.29E-07 -6.48E+00 63.27 0.084 0.01 0.046 65 
4.29E-07 -6.37E+00 63.31 0.062 0.014 0.06 65 
2.65E-06 -5.58E+00 49.54 0.048 0.086 0.373 65 
3.44E-06 -5.46E+00 47.55 0.23 0.112 0.485 65 
4.45E-06 -5.35E+00 46.11 0.19 0.145 0.63 65 
5.78E-06 -5.24E+00 44.73 0.59 0.191 0.821 65 
7.49E-06 -5.13E+00 44.73 0.52 0.249 1.07 65 
9.71E-06 -5.01E+00 44.49 0.55 0.326 1.396 65 
1.26E-05 -4.90E+00 43.41 0.56 0.43 1.826 65 
1.63E-05 -4.79E+00 43.24 0.35 0.569 2.395 65 
2.12E-05 -4.67E+00 43.31 0.35 0.756 3.151 65 
2.75E-05 -4.56E+00 43.25 1.50 1.014 4.165 65 
3.57E-05 -4.45E+00 42.93 1.30 1.375 5.54 65 
4.63E-05 -4.33E+00 42.08 0.97 1.89 7.43 65 
6.00E-05 -4.22E+00 43.18 0.71 2.652 10.082 65 
 
Table C 3 Specific conductivity vs. surfactant concentration 
Phy-3-12 
Concentration (M) Specific conductivity (S/cm) Average± SD 
0 0.79 0.75 0.77 0.77 ± 0.020 
6.17E-06 1.28 1.31 1.31 1.30 ± 0.017 
1.23E-05 1.84 1.84 1.86 1.85 ± 0.012 
1.84E-05 2.36 2.38 2.39 2.38 ± 0.015 
2.45E-05 2.85 2.92 2.91 2.89 ± 0.038 
3.05E-05 3.39 3.40 3.40 3.40 ± 0.006 
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3.65E-05 3.86 3.86 3.87 3.86 ± 0.0o6 
4.85E-05 4.73 4.76 4.76 4.75 ± 0.017 
6.03E-05 5.49 5.54 5.56 5.53 ± 0.036 
7.20E-05 6.06 6.08 6.09 6.08 ± 0.015 
8.37E-05 6.58 6.59 6.61 6.59 ± 0.015 
9.52E-05 7.00 7.05 7.06 7.04 ± 0.032 
1.06E-04 7.41 7.45 7.45 7.44 ± 0.023 
         1.18E-04 7.78 7.82 7.82 7.81 ± 0.023 
1.29E-04 8.14 8.15 8.16 8.15 ± 0.010 
1.46E-04 8.73 8.71 8.69 8.71 ± 0.020 
1.73E-04 9.42 9.40 9.43 9.42 ± 0.016 
1.99E-04 10.25 10.26 10.24 10.25 ± 0.010 
2.25E-04 10.75 11.01 11.01 10.92 ± 0.015 
2.75E-04 12.32 12.34 12.30 12.32 ± 0.020 
3.23E-04 13.65 13.68 13.70 13.68 ± 0.025 
 
Phy-3-16 
Concentration 
(mM) Specific conductivity (S/cm) Average± SD 
0 1.07 1.06 1.07 1.07 ± 0.006 
1.13E-04 1.13 1.12 1.13 1.13 ± 0.006 
1.69E-03 1.17 1.18 1.19 1.18 ± 0.01 
2.82E-03 1.26 1.28 1.25 1.26± 0.015 
3.93E-03 1.32 1.36 1.35 1.34 ± 0.021 
4.49E-03 1.38 1.37 1.41 1.38 ± 0.021 
5.05E-03 1.41 1.43 1.41 1.42 ± 0.012 
5.60E-03 1.45 1.47 1.47 1.46 ± 0.012 
6.70E-03 1.57 1.53 1.55 1.55 ± 0.020 
7.25E-03 1.61 1.60 1.64 1.62 ± 0.021 
8.35E-03 1.70 1.67 1.67 1.68 ± 0.017 
9.44E-03 1.78 1.77 1.81 1.79 ± 0.021 
1.11E-02 1.94 1.96 1.94 1.95 ± 0.012 
1.21E-02 2.03 2.06 2.06 2.05 ± 0.017 
1.37E-02 2.22 2.22 2.23 2.22 ± 0.006 
1.64E-02 2.45 2.48 2.47 2.47 ± 0.015 
1.90E-02 2.74 2.72 2.72 2.73 ± 0.012 
2.42E-02 3.14 3.16 3.17 3.16 ± 0.015 
2.92E-02 3.55 3.56 3.54 3.55 ± 0.010 
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3.41E-02 3.94 3.89 3.93 3.92 ± 0.026 
3.89E-02 4.2 4.23 4.19 4.21 ± 0.021 
4.81E-02 4.73 4.76 4.78 4.76 ± 0.025 
 
Phy-3-18 
Concentration 
(mM) Specific conductivity (S/cm) Average± SD 
4.41E-03 1.07 1.09 1.09 1.08 ± 0.012 
4.85E-03 1.11 1.14 1.13 1.13 ± 0.015 
5.28E-03 1.17 1.17 1.16 1.17 ± 0.006 
5.72E-03 1.20 1.18 1.20 1.19 ± 0.012 
8.72E-03 1.60 1.62 1.59 1.60± 0.015 
9.57E-03 1.69 1.68 1.72 1.70 ± 0.021 
1.08E-02 1.89 1.86 1.90 1.88 ± 0.021 
1.29E-02 2.17 2.16 2.19 2.17 ± 0.015 
1.50E-02 2.46 2.45 2.44 2.45 ± 0.010 
1.70E-02 2.73 2.71 2.71 2.72 ± 0.015 
2.10E-02 3.18 3.22 3.17 3.19 ± 0.026 
2.49E-02 3.48 3.56 3.52 3.52 ± 0.040 
2.88E-02 3.83 3.85 3.84 3.84 ± 0.010 
3.25E-02 4.04 4.09 4.08 4.07 ± 0.026 
3.97E-02 4.45 4.5 4.48 4.48 ± 0.025 
5.33E-02 5.38 5.41 5.45 5.41 ± 0.035 
7.15E-02 6.22 6.26 6.29 6.26 ± 0.035 
8.51E-02 6.86 6.88 6.93 6.89 ± 0.036 
9.27E-02 7.25 7.28 7.30 7.28 ± 0.025 
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Appendix D Fluorescence microscopic images  
 
    
 Figure D 1. EGFP images for the cells treated with complexes comprised of phy-3-
18 at charge ratio of 2:1 (a), 5:1 (b), and 10:1 (c), and complexes comprised of 16-3-
16 at 2:1. 
Appendix E Transfection data 
Table E 1 Preliminary investigation on transfection of the phytanyl gemini surfactants 
in OVCAR-3 cells (data for Figure 3.8). 
 EGFP expression 
(%) 
 EGFP expression 
(%) 
No treatment 0.03 ± 0.01 Phy-3-18 13.28 ± 2.16 
Lipofectamine TM 2000 34.56 ± 7.73 16-3-16 4.82 ± 0.22 
Plasmid only 0.05 ± 0.05 12-7NH-12 1.43 ± 0.99 
Plasmid with DOPE 0.08 ± 0.03 Phy-7NH-12 0.08 
Phy-3-12 9.35 ± 0.94 Phy-7NH-16 0.52 
Phy-3-16 13.74 ± 3.39 Phy-7NH-18 0.3 
  
a b 
c d 
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Table E 2 EGFP expression in OVCAR-3 (data for Figure 4.4). 
  EGFP expression (%)   
No treatment 0.01± 0.006    
Lipofectamine TM 2000 32.18 ± 1.56    
Plasmid only 0.09 ± 0.02    
Plamid+DOPE 0.11 ± 0.04    
  2:1 5:1 10:1 20:1 
Phy-3-12  9.44 ± 1.81 12.35 ± 1.68 9.48 ± 2.17 0.32 
phy-3-16  16.35 ± 1.97 15.63 ± 0.56 12.69 ± 0.77 0.74 
phy-3-18  9.92 ± 0.99 15.12 ± 0.76 10.77 ± 0.92 0.96 
16-3-16  11.19 ± 1.72 8.26 ± 0.59 3.56 ± 0.68 2.36 
 
Table E 3 Cytoxicity in OVCAR-3 cells (expressed as cell viability) (data for Figure 
4.5) 
 Cell viability (%) 
No treatment 86.14 ± 2.52    
  2:1 5:1 10:1 
Phy-3-12  80.57 ± 2.26 80.02 ± 2.12 69.41 ± 0.26 
phy-3-16  80.24 ± 1.06 73.91 ± 2.86 59.75 ± 4.76 
phy-3-18  76.65 ± 1.09 69.61 ± 0.16 64.99 ± 1.92 
16-3-16  70.37 ± 0.70 55.93 ± 0.31 46.49 ± 4.28 
 
 
 
 
